
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Surface‐Engineered Natural Killer Cell‐Derived Small Extracellular Vesicles Induce Potent Anti‐Tumour Effects in Lung Cancer Cells - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4ABEB8AF2C7A305ABEB0051D92E4D.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="jebiol">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365385/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Extracellular Biology">
<meta name="citation_title" content="Surface‐Engineered Natural Killer Cell‐Derived Small Extracellular Vesicles Induce Potent Anti‐Tumour Effects in Lung Cancer Cells">
<meta name="citation_author" content="Sung‐Min Kang">
<meta name="citation_author_institution" content="Department of Molecular Medicine, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea">
<meta name="citation_author" content="Dokyung Jung">
<meta name="citation_author_institution" content="Department of Molecular Medicine, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea">
<meta name="citation_author" content="Soojeong Noh">
<meta name="citation_author_institution" content="Department of New Biology, DGIST, Daegu, Republic of Korea">
<meta name="citation_author" content="Sanghee Shin">
<meta name="citation_author_institution" content="Department of New Biology, DGIST, Daegu, Republic of Korea">
<meta name="citation_author" content="Minju Kim">
<meta name="citation_author_institution" content="Department of Molecular Medicine, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea">
<meta name="citation_author" content="Hanchae Cho">
<meta name="citation_author_institution" content="Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu, Republic of Korea">
<meta name="citation_author" content="Byungheon Lee">
<meta name="citation_author_institution" content="Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu, Republic of Korea">
<meta name="citation_author_institution" content="Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea">
<meta name="citation_author" content="Kyungmoo Yea">
<meta name="citation_author_institution" content="Department of New Biology, DGIST, Daegu, Republic of Korea">
<meta name="citation_author_institution" content="New Biology Research Center, DGIST, Daegu, Republic of Korea">
<meta name="citation_author" content="Moon‐Chang Baek">
<meta name="citation_author_institution" content="Department of Molecular Medicine, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea">
<meta name="citation_publication_date" content="2025 Aug 20">
<meta name="citation_volume" content="4">
<meta name="citation_issue" content="8">
<meta name="citation_firstpage" content="e70080">
<meta name="citation_doi" content="10.1002/jex2.70080">
<meta name="citation_pmid" content="40843441">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365385/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365385/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365385/pdf/JEX2-4-e70080.pdf">
<meta name="description" content="Small extracellular vesicles (sEVs) derived from natural killer (NK) cells possess inherent anti‐tumour activity and offer the advantages of cell‐free therapy. In this study, we genetically engineered NK‐sEVs to express interleukin 15 (IL15), an ...">
<meta name="og:title" content="Surface‐Engineered Natural Killer Cell‐Derived Small Extracellular Vesicles Induce Potent Anti‐Tumour Effects in Lung Cancer Cells">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Small extracellular vesicles (sEVs) derived from natural killer (NK) cells possess inherent anti‐tumour activity and offer the advantages of cell‐free therapy. In this study, we genetically engineered NK‐sEVs to express interleukin 15 (IL15), an ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365385/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12365385">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/jex2.70080"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/JEX2-4-e70080.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365385%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12365385/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12365385/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365385/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-jebiol.png" alt="Journal of Extracellular Biology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Journal of Extracellular Biology" title="Link to Journal of Extracellular Biology" shape="default" href="https://doi.org/10.1002/jex2.70080" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Extracell Biol</button></div>. 2025 Aug 20;4(8):e70080. doi: <a href="https://doi.org/10.1002/jex2.70080" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/jex2.70080</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Extracell%20Biol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Extracell%20Biol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Extracell%20Biol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Extracell%20Biol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Surface‐Engineered Natural Killer Cell‐Derived Small Extracellular Vesicles Induce Potent Anti‐Tumour Effects in Lung Cancer Cells</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kang%20SM%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Sung‐Min Kang</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Sung‐Min Kang</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Molecular Medicine, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kang%20SM%22%5BAuthor%5D" class="usa-link"><span class="name western">Sung‐Min Kang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jung%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Dokyung Jung</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Dokyung Jung</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Molecular Medicine, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jung%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dokyung Jung</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Noh%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Soojeong Noh</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Soojeong Noh</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of New Biology, DGIST, Daegu, Republic of Korea</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Noh%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Soojeong Noh</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shin%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Sanghee Shin</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Sanghee Shin</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of New Biology, DGIST, Daegu, Republic of Korea</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shin%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sanghee Shin</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kim%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Minju Kim</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Minju Kim</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Molecular Medicine, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kim%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Minju Kim</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cho%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Hanchae Cho</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Hanchae Cho</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu, Republic of Korea</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cho%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hanchae Cho</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lee%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Byungheon Lee</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Byungheon Lee</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu, Republic of Korea</div>
<div class="p">
<sup>
<sup>4</sup>
</sup>Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lee%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Byungheon Lee</span></a>
</div>
</div>
<sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yea%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Kyungmoo Yea</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Kyungmoo Yea</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of New Biology, DGIST, Daegu, Republic of Korea</div>
<div class="p">
<sup>
<sup>5</sup>
</sup>New Biology Research Center, DGIST, Daegu, Republic of Korea</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yea%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kyungmoo Yea</span></a>
</div>
</div>
<sup>2,</sup><sup>5,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Baek%20MC%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Moon‐Chang Baek</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Moon‐Chang Baek</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Molecular Medicine, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Baek%20MC%22%5BAuthor%5D" class="usa-link"><span class="name western">Moon‐Chang Baek</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="jex270080-aff-0001">
<sup>
<sup>1</sup>
</sup>Department of Molecular Medicine, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea</div>
<div id="jex270080-aff-0002">
<sup>
<sup>2</sup>
</sup>Department of New Biology, DGIST, Daegu, Republic of Korea</div>
<div id="jex270080-aff-0003">
<sup>
<sup>3</sup>
</sup>Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu, Republic of Korea</div>
<div id="jex270080-aff-0004">
<sup>
<sup>4</sup>
</sup>Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute (CMRI), School of Medicine, Kyungpook National University, Daegu, Republic of Korea</div>
<div id="jex270080-aff-0005">
<sup>
<sup>5</sup>
</sup>New Biology Research Center, DGIST, Daegu, Republic of Korea</div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jun 30; Received 2024 May 20; Accepted 2025 Jul 22; Collection date 2025 Aug.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Journal of Extracellular Biology</em> published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12365385  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40843441/" class="usa-link">40843441</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<p>Small extracellular vesicles (sEVs) derived from natural killer (NK) cells possess inherent anti‐tumour activity and offer the advantages of cell‐free therapy. In this study, we genetically engineered NK‐sEVs to express interleukin 15 (IL15), an anti‐tumour cytokine, and the monoclonal antibody cetuximab on their surface, creating a potent anti‐tumour immunotherapy with enhanced tumour‐targeting capabilities. These IL15‐ and cetuximab‐tethered NK‐sEVs (eEVs) were generated using lentivirus‐based modification. eEVs selectively bound to EGFR<sup>+</sup> cancer cells in vitro, confirming cetuximab‐mediated targeting. Compared to control NK‐sEVs, eEVs exhibited significantly enhanced cytotoxicity by directly inducing cancer cell death and promoting NK cell‐mediated killing. In a lung cancer mouse model, eEVs selectively accumulated in tumours and exhibited significant anti‐tumour efficacy. Notably, their administration, alone or in combination with anti‐PD‐1 antibody therapy, effectively suppressed tumour growth. Overall, our results indicate that genetically engineered NK‐sEVs, equipped with IL15 and cetuximab, exhibit potent anti‐tumour activity and tumour‐targeting capabilities. These findings suggest that eEVs hold significant potential as a novel immunotherapeutic strategy for cancer treatment.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> cetuximab, interleukin 15, lung cancer, natural killer cells, small extracellular vesicles</p></section></section><section class="abstract" id="jex270080-abs-0001"><hr class="headless">
<p>We genetically engineered NK‐92 cells to produce NK‐sEVs expressing IL15 and cetuximab. These eEVs directly killed lung cancer cells and promoted immune cell‐mediated cytotoxicity. Compared to cEVs, eEVs showed enhanced cancer‐targeting abilities and significant anti‐tumour effects.
</p>
<section class="bt xbox font-sm" id="boxed-text1"><p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f8e/12365385/5e0508f990cc/JEX2-4-e70080-g003.jpg" loading="lazy" id="jats-graphic-1" height="111" width="180" alt="graphic file with name JEX2-4-e70080-g003.jpg"></p></section></section><section id="jex270080-sec-0010"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Lung cancer exhibits a globally elevated incidence and the highest mortality rate among all cancers (Siegel et al. <a href="#jex270080-bib-0039" class="usa-link" aria-describedby="jex270080-bib-0039">2023</a>). The most common histological subtype of lung cancer is non‐small cell lung cancer (NSCLC), representing approximately 85% of all lung cancer cases, which comprises adenocarcinoma, large cell carcinoma, and squamous cell carcinoma (Testa et al. <a href="#jex270080-bib-0041" class="usa-link" aria-describedby="jex270080-bib-0041">2018</a>). Early‐stage NSCLC is typically treated through surgical resection, whereas advanced‐stage cases are extensively treated using chemotherapy (Cheng et al. <a href="#jex270080-bib-0003" class="usa-link" aria-describedby="jex270080-bib-0003">2021</a>). Molecular targeted therapy is commonly recommended for patients with NSCLC who have specific genetic mutations, and the most successful cases involve the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as targeted therapy for NSCLC with EGFR mutations (Liu, Chen, et al. <a href="#jex270080-bib-0023" class="usa-link" aria-describedby="jex270080-bib-0023">2022</a>; Ji et al. <a href="#jex270080-bib-0011" class="usa-link" aria-describedby="jex270080-bib-0011">2006</a>). However, in NSCLC, where targetable mutations are limited, the development of novel therapies for patients without specific mutations is crucial.</p>
<p>Small extracellular vesicles (sEVs) are nanosized lipid bilayer vesicles, typically less than 200 nm in diameter, that are secreted by various cell types and play important roles in intercellular communication (Théry et al. <a href="#jex270080-bib-0042" class="usa-link" aria-describedby="jex270080-bib-0042">2002</a>; El Andaloussi et al. <a href="#jex270080-bib-0007" class="usa-link" aria-describedby="jex270080-bib-0007">2013</a>). This is essential for maintaining cellular homeostasis and influencing both pathology and physiology. Moreover, sEVs have several advantages, such as excellent biocompatibility, low immunogenicity, high stability and a unique cellular uptake mechanism, thus making them highly promising for anti‐tumour therapy (Herrmann et al. <a href="#jex270080-bib-0010" class="usa-link" aria-describedby="jex270080-bib-0010">2021</a>; Xu et al. <a href="#jex270080-bib-0050" class="usa-link" aria-describedby="jex270080-bib-0050">2018</a>). However, despite these strengths, currently developed sEV‐based therapeutics face challenges of insufficient efficacy and low delivery efficiency (Li et al. <a href="#jex270080-bib-0020" class="usa-link" aria-describedby="jex270080-bib-0020">2019</a>). Therefore, to overcome these limitations and exploit the advantages of sEVs, the development of modifications is essential to enhance their therapeutic efficacy and targeting capabilities (Luan et al. <a href="#jex270080-bib-0024" class="usa-link" aria-describedby="jex270080-bib-0024">2017</a>; Xu et al. <a href="#jex270080-bib-0049" class="usa-link" aria-describedby="jex270080-bib-0049">2020</a>).</p>
<p>Natural killer (NK) cells, integral components of the innate immune system, serve as frontline defenders against pathogens, tumour progression, and metastasis (Cerwenka and Lanier <a href="#jex270080-bib-0001" class="usa-link" aria-describedby="jex270080-bib-0001">2001</a>; Vivier et al. <a href="#jex270080-bib-0044" class="usa-link" aria-describedby="jex270080-bib-0044">2008</a>). sEVs derived from NK cells (NK‐sEVs) encapsulate microRNA, perforin, granzyme B, Fas ligand, and other tumour‐killing substances during biogenesis, thereby exhibiting their cytotoxic effects against various tumour cells (Zhu et al. <a href="#jex270080-bib-0054" class="usa-link" aria-describedby="jex270080-bib-0054">2017</a>; Kang et al. <a href="#jex270080-bib-0015" class="usa-link" aria-describedby="jex270080-bib-0015">2021</a>; Kaban et al. <a href="#jex270080-bib-0014" class="usa-link" aria-describedby="jex270080-bib-0014">2021</a>; Neviani et al. <a href="#jex270080-bib-0031" class="usa-link" aria-describedby="jex270080-bib-0031">2019</a>). NK‐sEVs maintain their anti‐tumour activity through a lack of signalling and metabolic pathways that are responsive to the inhibitory tumour microenvironment (TME) (Melaiu et al. <a href="#jex270080-bib-0028" class="usa-link" aria-describedby="jex270080-bib-0028">2020</a>). Therefore, NK‐sEVs may be considered as an alternative cancer treatment strategy that is capable of overcoming the suppressive TME.</p>
<p>In this study, membrane‐bound cytokine technology was used to genetically modify human NK cells, to exploit the potential of NK‐sEVs. Engineered NK‐sEVs (eEVs) were designed to surface‐express interleukin 15 (IL15) and the EGFR inhibitor cetuximab. Each of the tethered molecules exhibited the capacity to augment tumour cytotoxicity and enhance cancer targeting. This study revealed that eEVs demonstrate anti‐tumour effects in lung cancer cells, exerting anti‐tumour efficacy through the induction of NK cell‐mediated cytotoxicity. Additionally, in a lung cancer mouse model, eEVs significantly inhibited tumour growth and, when used in combination with the anti‐PD‐1 antibody (αPD‐1 Ab), enhanced anti‐tumour efficacy. In conclusion, these results suggest that strategic modifications to NK‐sEVs may further enhance their anti‐tumour efficacy and target specificity, indicating their potential applications for novel cancer immunotherapy.</p></section><section id="jex270080-sec-0020"><h2 class="pmc_sec_title">2. Materials and Methods</h2>
<section id="jex270080-sec-0030"><h3 class="pmc_sec_title">2.1. Cell Culture</h3>
<p>All cell lines were purchased from the American Type Culture Collection and cultured at 37°C in a 5% CO<sub>2</sub> humidified atmosphere. Human NK‐92 cells were cultured in Minimum Essential Medium (MEM) Alpha medium (Gibco, USA) supplemented with 12.5% foetal bovine serum (FBS; Hyclone, USA), 12.5% horse serum (Invitrogen, USA), 0.2 mM inositol (Sigma‐Aldrich, USA), 0.1 mM 2‐mercaptoethanol (Sigma‐Aldrich), 0.02 mM folic acid (Sigma‐Aldrich), and 1% penicillin/streptomycin (PS; Hyclone). Additionally, the culture medium for NK‐92 cells was consistently supplemented with 100 IU/mL of interleukin 2 (IL2; R&amp;D Systems, USA), unless specified otherwise. A549‐Luc2 (human lung cancer cell lines) cells were cultured in Roswell Park Memorial Institute Medium (RPMI)‐1640 (Hyclone) medium with 10% FBS and 1% PS. LL/2‐Luc2 (mouse Lewis lung carcinoma cell lines) and HEK293FT cells were maintained in Dulbecco's Modified Eagle's Medium (Hyclone) with 10% FBS and 1% PS.</p></section><section id="jex270080-sec-0040"><h3 class="pmc_sec_title">2.2. Lentivirus Preparation</h3>
<p>The pLV2 plasmid encoding IL15, sourced from a human cytokine library used in a prior study (Zha et al. <a href="#jex270080-bib-0053" class="usa-link" aria-describedby="jex270080-bib-0053">2017</a>), and the cetuximab single‐chain variable fragment sequence (scFv), obtained from DrugBank (Accession Number: DB00002), were cloned onto the same library‐based pLV2 plasmid (Zha et al. <a href="#jex270080-bib-0053" class="usa-link" aria-describedby="jex270080-bib-0053">2017</a>). The IL15 vector was designed to express the following components sequentially: the IL2 signalling sequence, the IL15 sequence, the Flag tag, the linker, the transmembrane domain of the platelet‐derived growth factor receptor (PDGFR), and mCherry. Similarly, the cetuximab vector was constructed to include the IL2 signalling sequence, cetuximab scFv, Flag tag, linker, and the PDGFR transmembrane domain. The linker, composed of repeating glycine and serine residues, connects the upstream sequence to the PDGFR transmembrane domain. This flexible design facilitates efficient protein expression, self‐stimulation and interaction with other cells. All relevant sequence information has been provided in Tables <a href="#jex270080-supinfo-0001" class="usa-link">S1</a> and <a href="#jex270080-supinfo-0001" class="usa-link">S2</a>. To generate a lentivirus that expressed either IL15 or cetuximab, HEK293FT cells were transfected with lipofectamine 3000 (Invitrogen) and a lentiviral plasmid mixture comprising equal amounts of pCMVD8.9, pVSVg, and pLV2 plasmids, as per the manufacturer's protocol. After overnight incubation, the DNA‐lipofectamine complex was removed and fresh medium was added to the culture dishes. The lentivirus‐containing supernatants were harvested after 48 h and filtered through a 0.45‐µm pore filter (Millipore, USA). The lentiviral titres were assessed utilizing the Lenti‐X p24 ELISA Kit (TaKaRa, Japan).</p></section><section id="jex270080-sec-0050"><h3 class="pmc_sec_title">2.3. Generation of Transformed NK Cells Using the Lentivirus</h3>
<p>To generate NK‐sEVs that express IL15 and cetuximab on their cell surface, NK cells were transduced with the lentivirus produced as described above. NK‐92 cells were seeded in 12‐well plates at a concentration of approximately 5.0 × 10<sup>5</sup> cells/well. Lentiviruses encoding IL15 and cetuximab were applied at a multiplicity of infection of 50 and supplemented with 10 µg/mL polybrene (Sigma‐Aldrich). The virus‐treated cell mixture was subjected to spinoculation at 1200 × <em>g</em> for 90 min at room temperature (RT), followed by overnight culture. The excess virus was removed, and the cells were replenished with fresh growth media.</p></section><section id="jex270080-sec-0060"><h3 class="pmc_sec_title">2.4. NK‐sEVs Isolation</h3>
<p>To isolate sEVs from the NK‐92 cells, the media was replaced with serum‐free MEM Alpha medium. After incubation for 24 h, the cell culture supernatants were collected and serially centrifuged at 300 × <em>g</em> for 5 min, 2500 × <em>g</em> for 15 min, and 10,000 × <em>g</em> for 30 min. The supernatants were then filtered through a 0.2‐µm syringe filter and centrifuged at 120,000 × <em>g</em> for 90 min at 4°C. The purified NK‐sEV pellets were resuspended in phosphate‐buffered saline (PBS, Hyclone).</p></section><section id="jex270080-sec-0070"><h3 class="pmc_sec_title">2.5. Transmission Electron Microscopy (TEM) Analysis</h3>
<p>The purified sEV pellets were fixed with 1.25% glutaraldehyde and 2.65% formaldehyde in 0.2 M sodium cacodylate buffer solution (pH 7.2). The prepared fixative was cooled to below 4°C. The cooled fixative was added to the EV emulsion to achieve a 1:1 ratio. The mixed sEV emulsion was stored at below 4°C for 1 h, with pipetting performed every 10 min to ensure uniformity. Before loading the fixed sEV solution, Ni TEM grids (200 mesh, TED Pella) were plasma cleaned under flowing O<sub>2</sub> and Ar for 1 min using an advanced plasma cleaner (Gatan, 950 M). 10 µL of the fixed sEV solution was loaded onto plasma‐cleaned grids for 10 min. Using filter paper, the remaining solution was removed, and then 10 µL of sodium cacodylate buffer was loaded for washing. The process of removing with filter paper and loading SC was repeated at 10 min intervals more than 15 times to sufficiently eliminate the fixative. To remove any remaining salts from the sodium cacodylate buffer, the process of removing with filter paper and loading deionized water was repeated at 10 min intervals more than 15 times. The Ni TEM grid loaded with fixed sEVs was slowly dried at atmospheric pressure. All loading and washing processes were conducted at temperatures below 4°C. The prepared sEVs were observed using TEM (FEI, Tecnai G2 F20 TWIN TMP) at an acceleration voltage of 200 kV.</p></section><section id="jex270080-sec-0080"><h3 class="pmc_sec_title">2.6. Nanoparticle Tracking Analysis (NTA)</h3>
<p>The size and concentration of sEVs in cell culture supernatants were measured using the NanoSight LM10 instrument. A monochromatic laser beam at 405 nm was used to analyse the nanoparticles, and a video of 1 min duration was captured at a rate of 30 frames/s with a camera level of 4. Particles within the commonly reported sEV size range (i.e., below 200 nm) were analysed in each field of view. However, it is acknowledged that the lower limit of reliable detection for NTA is approximately 70–80 nm due to the optical limitations of the technique. The Brownian motion of the particles was tracked and analysed using NTA software (version 2.3, NanoSight).</p></section><section id="jex270080-sec-0090"><h3 class="pmc_sec_title">2.7. Fluorescent Labelling of NK‐sEVs</h3>
<p>After isolation by ultracentrifugation, NK‐sEVs were resuspended in sterile PBS. For fluorescent labelling, the sEVs were incubated with either 1,1'‐Dioctadecyl‐3,3,3',3'‐Tetramethylindotricarbocyanine Iodide (DiR, <a href="https://www.ncbi.nlm.nih.gov/nuccore/D12731" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">D12731</a>; Invitrogen) or 1,1'‐Dioctadecyl‐3,3,3',3'‐Tetramethylindocarbocyanine Perchlorate (DiI, D3911; Invitrogen), both at a final concentration of 10 µM, at RT for 30 min in the dark. Following incubation, free dye was removed using tangential flow filtration (TFF) with hollow fibre polysulfone membranes (0.5 mm fibre ID; D02‐S05U‐05‐N; Repligen, USA), accompanied by a 10‐fold volume exchange with PBS to ensure thorough washing. A PBS‐only control was processed in parallel using the same DiI labelling and TFF washing steps and served as a free dye control for in vitro targeting experiments.</p></section><section id="jex270080-sec-0100"><h3 class="pmc_sec_title">2.8. Total RNA Isolation and Quantitative Real‐Time PCR</h3>
<p>One microgram of RNA isolated from NK‐92 cells using the Direct‐zol RNA Microprep kit (R2060; Zymo Research, USA) was reverse transcribed into cDNA using the Omniscript Reverse Transcription kit (QIAGEN, Germany), following the manufacturer's protocols. To assess the expression levels of perforin, Fas ligand, granzyme B, and interferon‐γ in NK cells, qRT‐PCR was conducted using the StepOne Plus instrument (Thermo Fisher, USA) and SYBR premix (4368577; Thermo Fisher). The sequences of these primers are listed in Table <a href="#jex270080-supinfo-0001" class="usa-link">S3</a>. The relative mRNA levels were determined using the comparative threshold cycle (2<sup>−ΔΔCt</sup>) analysis method, with normalization to GAPDH mRNA levels.</p></section><section id="jex270080-sec-0110"><h3 class="pmc_sec_title">2.9. Flow Cytometry</h3>
<p>To confirm IL15 and cetuximab expression on NK cell surfaces, cells were washed with PBS and fixed with 4% paraformaldehyde. The cells were further stained with their respective primary antibodies (anti‐IL15; MAB2471; R&amp;D systems, and anti‐cetuximab; MAB9626; R&amp;D systems) and then with the corresponding secondary antibodies (anti‐mouse IgG‐Alexa Fluor 488; A‐110051; Invitrogen, and anti‐rabbit IgG‐Alexa Fluor 488; A‐11008; Invitrogen). To evaluate the changes in cytotoxicity of NK‐92 cells induced by NK‐sEVs, we assessed the expression of granzyme B. The NK‐92 cells were fixed and then permeabilized with 0.1% Triton X‐100 in PBS. Cells were blocked and stained with the anti‐granzyme B (12‐8899‐41; Invitrogen). All experiments were conducted using the same number of cells within each experimental set to ensure consistency in protein expression analysis by flow cytometry. Samples were analysed using the CytoFLEX system (Beckman Coulter, USA) and FlowJo software v10 (BD, USA).</p></section><section id="jex270080-sec-0120"><h3 class="pmc_sec_title">2.10. Nanoflow Cytometry</h3>
<p>sEV proteins were analysed using nanoflow cytometry as previously described (Choi et al. <a href="#jex270080-bib-0006" class="usa-link" aria-describedby="jex270080-bib-0006">2019</a>). The purified NK‐sEVs were obtained as described in Section <a href="#jex270080-sec-0060" class="usa-link">2.4</a>. Briefly, sEVs were incubated with primary antibodies (anti‐IL15 [MAB2471; R&amp;D Systems], anti‐cetuximab [MAB9626; R&amp;D Systems], anti‐CD63 [ab68418; Abcam], and anti‐CD9 [ab2215; Abcam]) for 2 h at RT, followed by incubation with fluorophore‐conjugated secondary antibodies (anti‐mouse IgG‐Alexa Fluor 488 [A‐110051; Invitrogen] and anti‐rabbit IgG‐Alexa Fluor 488 [A‐11008; Invitrogen]) for 1 h at RT in the dark. Unbound antibodies were removed by ultracentrifugation at 120,000 × <em>g</em> for 90 min. Nanoflow cytometry was performed on a CytoFLEX system (Beckman Coulter) using the 405‐nm violet laser for side scatter (V‐SSC). The V‐SSC threshold was manually set to 2000 in the height channel. The flow rate was maintained at 10 µL/min, and the event rate was kept below 1000 events/sec to minimize swarm detection. Calibration was performed using 100‐, 150‐, 200‐, and 300‐nm polystyrene beads (Thermo Scientific 3000 Series Nanosphere Size Standards; 3100A, 3150A, 3200A, 3300A). sEVs were gated based on the scatter profile corresponding to the 100–200 nm bead range. Although polystyrene beads have a higher refractive index than biological vesicles, they were used here as a conventional reference for relative sizing, acknowledging that this may underestimate the true size of sEVs. The gating strategy is illustrated in Figure <a href="#jex270080-supinfo-0001" class="usa-link">S3</a>. Data were acquired and analysed using the CytoFLEX system and FlowJo software. All experiments were conducted using an equal number of sEV particles within each experimental set to ensure consistency in protein expression analysis. Appropriate negative controls (unstained sEVs and IgG isotype controls) were included to validate gating accuracy and account for nonspecific antibody binding.</p></section><section id="jex270080-sec-0130"><h3 class="pmc_sec_title">2.11. Immunocytochemistry (ICC)</h3>
<p>A549 or SW620 cells (1 × 10⁴ cells/well) were incubated with DiI‐labelled sEVs (5 × 10⁷ particles) for 1.5 h in the dark to prevent photobleaching. After incubation, the cells were washed with PBS and fixed with 4% paraformaldehyde for 10 min at RT. The fixed cells were then washed, stained with DAPI, and mounted using a fluorescence‐compatible mounting solution. Fluorescence images were acquired using a ZEISS fluorescence microscope.</p></section><section id="jex270080-sec-0140"><h3 class="pmc_sec_title">2.12. Cell Viability Assay</h3>
<p>To investigate the direct cytotoxic effects of NK‐sEVs on lung cancer cells, A549‐Luc2 cells were seeded into 96‐well plates at a density of 1 × 10<sup>4</sup> cells per well and incubated overnight. After incubation, the cells were treated with NK‐sEVs (cEVs, iEVs, aEVs, or eEVs) under equal particle conditions (2 × 10⁸ or 5 × 10⁸ particles) for 24 h to evaluate cancer cell proliferation and viability. Cell viability was determined using the CellTiter 96 AQueous One Solution Cell Proliferation Assay System (G3582, Promega, USA), which is based on the MTS assay, with absorbance measured at 490 nm using a VersaMax Microplate Reader (Molecular Devices, USA). For the in vivo imaging system (IVIS) analysis, A549‐Luc2 cells were treated with NK‐sEVs, and D‐luciferin (P/N 122799, PerkinElmer, USA) was used as the substrate, and the luminescence was analysed using the IVIS software.</p></section><section id="jex270080-sec-0150"><h3 class="pmc_sec_title">2.13. NK Cell‐Mediated Cytotoxicity Assay (Co‐Culture assay)</h3>
<p>NK‐92 cells were pre‐stimulated for 24 h with NK‐sEVs (cEVs, iEVs, aEVs, or eEVs) using an equal number of particles for each type of NK‐sEV. The sEV‐pre‐treated NK cells (effector cells, E) were co‐cultured with cancer cells (target cells, T), as previously described (Shin et al. <a href="#jex270080-bib-0037" class="usa-link" aria-describedby="jex270080-bib-0037">2022</a>). A549 cells (1 × 10<sup>4</sup> cells/well) were used at a ratio of T:E = 1:0, 1:2, and 1:4. After co‐culture, MTS reagent was added to each well and incubated for 2 h, followed by absorbance measurement at 490 nm. For the IVIS analysis, A549‐Luc2 cells were treated with sEV‐pre‐treated NK, and D‐luciferin was used as the substrate, and the luminescence was analysed using the IVIS software.</p></section><section id="jex270080-sec-0160"><h3 class="pmc_sec_title">2.14. Western Blotting</h3>
<p>To analyse sEV proteins, 15 µg of NK‐sEV lysates were separated by SDS‐PAGE (Invitrogen) and transferred onto nitrocellulose membranes (Invitrogen). The membranes were blocked with 5% skim milk in TBS‐T at RT for 1 h, probed with the respective primary antibodies overnight at 4°C, and then incubated with a horseradish peroxidase (HRP)‐linked secondary antibody at RT for 1 h. Membranes were imaged on ChemiDoc Imagers (Bio‐Rad, USA) using enhanced chemiluminescence (ECL) detection reagents (Thermo Fisher Scientific) and analysed by Image Lab software (Bio‐Rad). All antibodies that were used in the experiments are listed below: anti‐IL15 (MAB2471; R&amp;D systems), anti‐cetuximab (MAB9626; R&amp;D systems), anti‐Alix (ab117600; Abcam), anti‐Tsg101 (ab30871; Abcam), anti‐CD63 (ab68418; Abcam), anti‐CD9 (ab2215; Abcam), and anti‐Grnayzme B (ab4059; Abcam).</p></section><section id="jex270080-sec-0170"><h3 class="pmc_sec_title">2.15. Studies Using Syngeneic and Xenograft Lung Cancer Mouse Models</h3>
<p>All animal experiments adhered to relevant guidelines and were approved by the Kyungpook National University (KNU) Institutional Animal Care and Use Committees (IACUCs). For the development of a syngeneic lung cancer mouse model, LL/2‐Luc2 cells were subcutaneously injected into 6‐week‐old male wild‐type C57BL/6 mice (Koatech Inc., Korea). Intravenous injections of cEVs or eEVs (1 × 10<sup>10</sup> particles) was administered every 2 days. For the combination therapy approach, αPD‐L1 Ab or IgG Ab (InVivoMAb, 10 mg/kg) were administered intraperitoneally every 3 days. Tumour growth was monitored every 2 days using digital callipers, and volume was calculated using the ellipsoid formula V = ½ (length × width<sup>2</sup>). After 2 weeks, mice were euthanized via CO<sub>2</sub> inhalation, and luminescence was assessed using the IVIS imaging system.</p></section><section id="jex270080-sec-0180"><h3 class="pmc_sec_title">2.16. Immunohistochemistry (IHC)</h3>
<p>First, 5 µm thick sections of paraffin‐embedded cancer tissues were fixed in 4% PFA. After deparaffinization with xylene, the slides were rehydrated with decreasing concentrations of ethanol before washing with PBS. Tissue slides in antigen retrieval buffer (ab93678; Abcam) were boiled for 10 min followed by cooling down at RT for 2 h. Hydrogen peroxide (3%) and 5% normal goat serum (Vector Laboratories, S‐1000) in PBS were used for blocking peroxidase and non‐specific binding, respectively. The slides were incubated with primary antibodies diluted in 5% normal goat serum (100 µL/slide) overnight at 4°C. After washing, secondary antibodies were added and incubated for 1 h. The slides were incubated with 200 µL DAB (Vector Laboratories, SK‐4100) at RT, counterstained with haematoxylin for 3 min, and then analysed using a bright‐field microscope. Quantification of Ki‐67–positive areas was performed using ImageJ software (NIH, USA).</p></section><section id="jex270080-sec-0190"><h3 class="pmc_sec_title">2.17. Statistical Analysis</h3>
<p>All values are presented as the mean ± standard error of the mean (SEM), as indicated for each point or graph. Data were analysed by the indicated tests using GraphPad Prism 10.0 software (GraphPad, USA). <em>p</em> values of &lt; 0.05 were considered statistically significant, and *, **, ***, and **** represent <em>p</em> &lt; 0.05, 0.01, 0.001, and 0.0001, respectively.</p></section></section><section id="jex270080-sec-0200"><h2 class="pmc_sec_title">3. Results</h2>
<section id="jex270080-sec-0210"><h3 class="pmc_sec_title">3.1. Generation of Surface‐Engineered NK‐Derived sEVs</h3>
<p>In this study, our first aim was to generate human NK cells that expressed cytokines and antibodies on their surface using lentiviruses, and then subsequently harvest the sEVs from these engineered NK cells. To achieve this, we established the optimal conditions for sEV isolation while preserving NK cell viability. To isolate NK‐sEVs, cells were cultured in serum‐free medium for 24 h, followed by collection of the conditioned medium and subsequent differential ultracentrifugation. Using NTA, the size distribution of NK‐sEVs was found to be predominantly below 200 nm, with a peak at approximately 115 nm (Figure <a href="#jex270080-fig-0001" class="usa-link">1a</a>). Furthermore, TEM images revealed that the prepared NK‐sEVs were spherical particles with an intact membrane structure (Figure <a href="#jex270080-fig-0001" class="usa-link">1b</a>). Notably, the isolated NK‐sEVs were free from significant contamination by non‐vesicular components, such as lipoproteins (Figure <a href="#jex270080-supinfo-0001" class="usa-link">S1</a>).</p>
<figure class="fig xbox font-sm" id="jex270080-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f8e/12365385/6db2831646ac/JEX2-4-e70080-g004.jpg" loading="lazy" id="jats-graphic-3" height="1000" width="778" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/jex270080-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Engineering of natural killer (NK) cells and the characteristics of their small extracellular vesicles (sEVs). (a) Nanoparticle tracking analysis (NTA) of NK cell‐derived sEVs (NK‐sEVs) revealed their size distribution, and a representative image of the particles is shown. (b) Transmission electron microscopy (TEM) imaging of a bare NK‐sEV; this analysis indicated that the sEVs were structurally intact. Scale bars = 100 nm. (c) Fluorescence image of NK cells on Day 3 post‐lentiviral infection: non‐infected control NK‐92 cells (cNKs), IL15‐tethered NK‐92 cells (iNKs), cetuximab‐tethered NK‐92 cells (aNKs), and IL15‐ and cetuximab‐tethered NK‐92 cells (eNKs). Infected cells were detected using mCherry (IL15) tags, and nuclei were stained with Hoechst. Scale bar = 50 µm. (d) Evaluation of IL15 and cetuximab expression on the surface of NK cells using flow cytometry. (e) Representative histogram (left) and quantification (right) of IL15 and cetuximab expression on the surface of NK‐sEVs: control NK‐sEVs (cEVs), IL15‐expressing NK‐sEVs (iEVs), cetuximab‐expressing NK‐sEVs (aEVs), and IL15‐ and cetuximab‐expressing NK‐sEVs (eEVs) (<em>n</em> = 3). (f) Flow cytometric histograms representing the expression levels of the sEV markers (CD63 and CD9) in NK‐sEVs: cEVs, iEVs, aEVs, and eEVs. (g) Immunoblot analysis of IL15, cetuximab, and sEV markers in NK‐sEVs: cEVs, iEVs, aEVs, and eEVs. The data are presented as the mean ± standard error of the mean (SEM). ****<em>p</em> &lt; 0.0001.</p></figcaption></figure><p>Next, we manipulated the NK cells through lentiviral infection to express IL15 or cetuximab. The lentiviruses employed a unique display format by using a flexible linker to connect IL15 or cetuximab to the NK cell plasma membrane. We generated NK cells that expressed only IL15 (iNK), only cetuximab (aNK), or both IL15 and cetuximab (eNK) on their surface through this lentiviral system. The presence of IL15 and cetuximab in the engineered NK cells was confirmed through conventional PCR, fluorescent imaging, and flow cytometric analysis (Figures <a href="#jex270080-fig-0001" class="usa-link">1c,d</a> and Figure <a href="#jex270080-supinfo-0001" class="usa-link">S2</a>). As expected, 72 h post‐lentiviral infection, IL15 bands were observed only in iNK and eNK cells, which were infected with IL15‐expressing lentivirus, while cetuximab bands were detected in aNK and eNK cells, which were transduced by cetuximab‐expressing lentivirus. (Figure <a href="#jex270080-supinfo-0001" class="usa-link">S2</a>). Fluorescence from mCherry that was linked to IL15 was exclusively observed in the iNKs and eNKs (Figure <a href="#jex270080-fig-0001" class="usa-link">1c</a>). The surface expression of IL15 and cetuximab on the NK cells was confirmed through flow cytometric analysis (Figure <a href="#jex270080-fig-0001" class="usa-link">1d</a>).</p>
<p>After successfully generating iNK, aNK, and eNK cells, we confirmed the expression of IL15 and cetuximab on the surface of their respective NK‐sEVs (iEVs, aEVs, and eEVs) through nanoflow cytometry and western blot analysis. Our results demonstrated that IL15 and cetuximab were displayed on the surface of eEVs as intended (Figures <a href="#jex270080-fig-0001" class="usa-link">1e,g</a> and Figure <a href="#jex270080-supinfo-0001" class="usa-link">S3</a>). Additionally, the expression of sEV markers was similarly confirmed not only in control NK‐sEVs (cEVs) but also in each of the engineered NK‐sEVs (iEVs, aEVs, and eEVs) (Figures <a href="#jex270080-fig-0001" class="usa-link">1f,g</a>; Figures <a href="#jex270080-supinfo-0001" class="usa-link">S3</a> and <a href="#jex270080-supinfo-0001" class="usa-link">S4</a>). Taken together, we successfully generated NK‐sEVs with IL15 alone, cetuximab alone, or both IL15 and cetuximab simultaneously tethered to their surface, and we confirmed their fundamental characteristics.</p></section><section id="jex270080-sec-0220"><h3 class="pmc_sec_title">3.2. EGFR‐Specific Targeting of Cetuximab‐Tethered eEVs to Cancer Cells In Vitro</h3>
<p>We investigated whether cetuximab expression on the NK‐sEV surface enhances selective delivery to EGFR‐expressing cancer cells. Given the specificity of cetuximab for EGFR, we hypothesized that the uptake of NK‐sEVs would be dependent on the EGFR expression level of target cells. To test this, A549 (EGFR‐positive) (Van Schaeybroeck et al. <a href="#jex270080-bib-0043" class="usa-link" aria-describedby="jex270080-bib-0043">2006</a>) and SW620 (EGFR‐negative) (Yang et al. <a href="#jex270080-bib-0051" class="usa-link" aria-describedby="jex270080-bib-0051">2004</a>) cancer cells were treated with PBS or DiI‐labelled NK‐sEVs for 4 h, followed by flow cytometry to quantify DiI‐positive cells. The PBS control underwent the same DiI staining and washing steps as the NK‐sEVs and was used as a free dye control. In A549 cells, cetuximab‐expressing NK‐sEVs (aEVs and eEVs) showed a significantly greater proportion of DiI‐positive cells compared to cEVs, whereas iEV uptake was similar to that of cEVs. However, in SW620 cells, no significant differences were observed across all NK‐sEV groups, regardless of surface modifications (Figure <a href="#jex270080-fig-0002" class="usa-link">2a</a>). Furthermore, ICC was performed, and confocal microscopy imaging confirmed that aEVs and eEVs exhibited greater binding to A549 cells than cEVs, whereas no differences were observed in SW620 cells (Figures <a href="#jex270080-fig-0002" class="usa-link">2b,c</a>). These results demonstrate that our eEVs, which display cetuximab scFv on their surface, bind to cancer cells more rapidly in an EGFR‐dependent manner and are delivered more efficiently than cEVs.</p>
<figure class="fig xbox font-sm" id="jex270080-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f8e/12365385/daf60bb8b024/JEX2-4-e70080-g001.jpg" loading="lazy" id="jats-graphic-5" height="989" width="700" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/jex270080-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Cetuximab‐tethered NK‐sEVs specifically target EGFR‐expressing cancer cells. (a) Representative histogram (left) and quantification (right) of flow cytometry analysis of DiI‐positive cells in A549 (EGFR‐positive) and SW620 (EGFR‐negative) cancer cell lines 4 h after treatment with PBS or DiI‐labelled NK‐sEVs (cEVs, iEVs, aEVs, or eEVs) at a concentration of 5 × 10⁸ particles (<em>n</em> = 3). PBS was subjected to the same DiI labelling and washing procedures as the NK‐sEVs to control for free dye artefacts. (b), (c) Representative immunocytochemistry (ICC) images of A549 (b) and SW620 (c) cells following 1.5 h of treatment with PBS or DiI‐labelled NK‐sEVs (cEVs, iEVs, aEVs, or eEVs) at a concentration of 5 × 10<sup>7</sup> particles. The data are presented as the mean ± SEM. ****<em>p</em> &lt; 0.0001. ns, not significant.</p></figcaption></figure></section><section id="jex270080-sec-0230"><h3 class="pmc_sec_title">3.3. Enhanced In Vitro Anti‐Tumour Effects on Lung Cancer Cells Due to Changes in the Cargo of eEVs</h3>
<p>We examined whether NK‐sEVs could reduce the viability of A549 human lung cancer cells. MTS analysis revealed that all NK‐sEVs inhibited A549 cell viability at all tested doses. Treatment with iEVs or eEVs, which express IL15 on their surface, significantly induced cancer cell death compared to treatment with cEVs. Notably, when 5 × 10⁸ particles of NK‐sEVs were administered, eEVs showed a markedly stronger inhibitory effect on A549 cell viability compared to other NK‐sEVs (Figure <a href="#jex270080-fig-0003" class="usa-link">3a</a>). A similar trend was observed in A549 cells that expressed luciferase (A549‐Luc2) when treated with each of the NK‐sEVs: cEVs, iEVs, aEVs, or eEVs (Figure <a href="#jex270080-fig-0003" class="usa-link">3b</a>). These results indicate that NK‐sEVs expressing IL15 on their surface exhibit stronger anti‐tumour effects than cEVs. Although aEVs were less effective than iEVs or eEVs, they still induced significant cancer cell death compared to cEVs (Figures <a href="#jex270080-fig-0003" class="usa-link">3a,b</a>). Since cetuximab is known to have a minimal impact on the survival of A549 cells (Mukohara et al. <a href="#jex270080-bib-0030" class="usa-link" aria-describedby="jex270080-bib-0030">2005</a>), the enhanced cancer cell‐killing ability of aEVs compared to cEVs suggests that cetuximab effectively targets cancer cells, allowing NK‐sEVs to exert their effects more efficiently.</p>
<figure class="fig xbox font-sm" id="jex270080-fig-0003"><h4 class="obj_head">FIGURE 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f8e/12365385/b4445030c7f2/JEX2-4-e70080-g002.jpg" loading="lazy" id="jats-graphic-7" height="404" width="800" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/jex270080-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Anti‐tumour effects of NK‐sEVs on lung cancer cells due to changes in NK‐sEV‐derived cytotoxic molecules. (a), (b) We assessed the viability of A549‐Luc2 cells treated with NK‐sEVs: cEVs, iEVs, aEVs, or eEVs. After treatment with NK‐sEVs at concentrations of 2 × 10<sup>8</sup> particles and 5 × 10<sup>8</sup> particles, cell viability was evaluated 24 h later using MTS analysis (<em>n</em> = 4) (a) and luminescence analysis (<em>n</em> = 5) (b). (c) Quantification of relative mRNA expression levels of perforin, Fas ligand, granzyme B, and interferon‐γ in control NK cells (cNKs) and various engineered NK cells (iNKs, aNKs, eNKs) as assessed by qRT‐PCR (<em>n</em> = 3). (d) Granzyme B protein expression within NK‐sEVs (cEVs, iEVs, aEVs, eEVs) was analysed by western blotting. The data are presented as the mean ± SEM. *<em>p</em> &lt; 0.05; **<em>p</em> &lt; 0.01; ***<em>p</em> &lt; 0.001; ****<em>p</em> &lt; 0.0001.</p></figcaption></figure><p>Next, we investigated how the engineered NK‐sEVs induced the death of lung cancer cells. Various mechanisms, such as the receptor–ligand‐mediated pathway and perforin‐and‐granzyme B‐mediated pathway, have been revealed to affect the cytotoxicity and targeting ability of NK cells in tumours (Russell and Ley <a href="#jex270080-bib-0033" class="usa-link" aria-describedby="jex270080-bib-0033">2002</a>). We measured the mRNA expression levels of cytotoxic molecules, including perforin, Fas ligand, interferon‐γ, and granzyme B, within each engineered NK cell using qRT‐PCR. We observed that all these factors were upregulated by at least 2.5‐fold in iNK and eNK cells, which express IL15 on their surface, compared to cNK cells. However, the expression of these genes in aNK cells, which express only cetuximab, showed no difference compared to that in cNK cells (Figure <a href="#jex270080-fig-0003" class="usa-link">3c</a>). These findings indicate that IL15‐expressed NK cells exhibit increased levels of cytotoxic molecules, which is consistent with previous studies showing that IL15 induces the activation of cytotoxic molecules in NK cells (Leong et al. <a href="#jex270080-bib-0018" class="usa-link" aria-describedby="jex270080-bib-0018">2014</a>; Zhu et al. <a href="#jex270080-bib-0055" class="usa-link" aria-describedby="jex270080-bib-0055">2019</a>; Widowati et al. <a href="#jex270080-bib-0047" class="usa-link" aria-describedby="jex270080-bib-0047">2020</a>). Additionally, when assessing the granzyme B protein levels within the cargo of sEVs derived from each engineered NK cell, we found that iEVs and eEVs expressing IL15 showed an increase of more than 1.5‐fold compared to cEVs or aEVs (Figure <a href="#jex270080-fig-0003" class="usa-link">3d</a>). These results collectively suggest that IL15 expression on the surface of NK cells leads to an increase in cytotoxic molecules within the cells, resulting in a greater payload of these molecules within the sEVs. Consequently, the enhanced anti‐tumour efficacy of eEVs expressing both IL15 and cetuximab, compared to sEVs expressing either IL15 or cetuximab alone, is likely due to the additive effect of the IL15‐induced increase in cytotoxic molecules and the enhanced targeting capability provided by cetuximab.</p></section><section id="jex270080-sec-0240"><h3 class="pmc_sec_title">3.4. eEV‐Mediated NK Cell Activation Reduces Lung Cancer Cell Viability</h3>
<p>We assessed whether eEVs could enhance immune cell‐mediated anti‐tumour effects in vitro. A co‐culture analysis was performed to evaluate the cytotoxicity of NK‐92 cells that were prestimulated by NK‐sEVs against lung cancer cells (Figure <a href="#jex270080-fig-0004" class="usa-link">4a</a>). MTS analysis showed that NK cells pre‐stimulated with IL15‐expressing NK‐sEVs (iEVs or eEVs) significantly increased lung cancer cell death compared to those pre‐stimulated with cEVs. In contrast, NK cells pre‐stimulated with cetuximab‐expressing aEVs did not exhibit a significant difference in cancer cell death compared to cEV‐treated cells (Figure <a href="#jex270080-fig-0004" class="usa-link">4b</a>). Furthermore, similar findings were observed when assessing the luciferase activity of the surviving A549‐Luc2 cells after co‐culture with NK‐92 cells (Figure <a href="#jex270080-fig-0004" class="usa-link">4c</a>).</p>
<figure class="fig xbox font-sm" id="jex270080-fig-0004"><h4 class="obj_head">FIGURE 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f8e/12365385/8b6a5117dc24/JEX2-4-e70080-g005.jpg" loading="lazy" id="jats-graphic-9" height="790" width="760" alt="FIGURE 4"></p>
<div class="p text-right font-secondary"><a href="figure/jex270080-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>NK cell‐mediated cancer cell killing by the in vitro treatment with eEVs. (a) Schematic of the co‐culture assay of A549‐Luc2 lung cancer cells (target cells, T) with NK‐92 cells (effector cells, E) that were pretreated with cEVs or eEVs. The viability of the lung cancer cells was measured using an MTS assay (b) or an in vitro bioluminescent assay (c) (<em>n</em> = 4). (b) Co‐culture assay of lung cancer cells with NK cells pretreated with NK‐sEVs (cEVs, iEVs, aEVs, or eEVs) at different ratios. (c) Representative image (left) and quantification graph (right) of the co‐culture assay. (d) Representative flow cytometric histograms (left) and bar graphs (right) showing the activity of NK‐92 cells after treatment with PBS control, NK‐sEVs (cEVs, iEVs, aEVs, or eEVs), or rIL2 (1000 IU) (<em>n</em> = 3). The data are presented as the mean ± SEM. **<em>p</em> &lt; 0.01; ***<em>p</em> &lt; 0.001; ****<em>p</em> &lt; 0.0001; and ns, not significant.</p></figcaption></figure><p>Subsequently, we investigated whether the NK‐sEVs influenced the activity of immune cells in vitro. After treating NK92 cells with each of the NK‐sEVs (cEVs, iEVs, aEVs, or eEVs), we measured the levels of granzyme B, a key indicator of NK cell cytotoxicity. When treated with cEVs or aEVs, the granzyme B expression was similar to that observed with PBS treatment. However, when treated with iEVs or eEVs, which express IL15 on their surface, NK cell activation significantly enhanced compared to treatment with PBS, cEVs, or aEVs (Figure <a href="#jex270080-fig-0004" class="usa-link">4d</a>). These results suggest that IL15 expressed on the surface of NK‐sEVs leads to the activation of NK cells, thereby inducing cancer cell death through immune cell‐mediated cytotoxicity.</p></section><section id="jex270080-sec-0250"><h3 class="pmc_sec_title">3.5. Analysis of Tumour‐Targeting Ability of eEVs in a Lung Cancer Mouse Model</h3>
<p>Having established that cetuximab‐EGFR interactions enhance eEV delivery to cancer cells in an in vitro system, we next examined whether this targeting capability remains effective in the more complex in vivo environment. To track NK‐sEVs in vivo, cEVs and eEVs were labelled with DiR and then intravenously injected into nude mice with A549‐Luc2 cell xenografts. After 24 h, the in vivo distribution was measured to assess the tumour‐targeting efficiency of NK‐sEVs. Unlike the cEV‐treated mice, those treated with eEVs exhibited fluorescence signals within the tumour (Figure <a href="#jex270080-fig-0005" class="usa-link">5a</a>). Fluorescence analysis was performed after collecting the tumour tissues, lungs, heart, liver, spleen, and kidneys of the mice. As shown in Figure <a href="#jex270080-fig-0005" class="usa-link">5b</a>, both the cEVs and eEVs primarily accumulated in the liver; however, the eEVs were uniquely detected in the tumour as well. Although a dedicated free dye–only control was not included in this in vivo analysis, both cEV and eEV samples were labelled and processed under identical conditions. Therefore, any potential background fluorescence due to free dye would likely be equally present in both groups. These data suggest that the enhanced fluorescence signal observed in the tumour region is attributable to the engineered targeting ability of eEVs rather than nonspecific dye distribution. This tumour‐targeting effect is attributed to the EGFR–cetuximab interaction.</p>
<figure class="fig xbox font-sm" id="jex270080-fig-0005"><h4 class="obj_head">FIGURE 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f8e/12365385/7668c52fa20a/JEX2-4-e70080-g007.jpg" loading="lazy" id="jats-graphic-11" height="191" width="700" alt="FIGURE 5"></p>
<div class="p text-right font-secondary"><a href="figure/jex270080-fig-0005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>In vivo targeting of DiR‐labelled eEVs to the xenograft tumours in mice. (a) After intravenous administration of 1 × 10<sup>10</sup> particles/mouse of DiR‐labelled cEVs or eEVs, in vivo fluorescence imaging in mice was performed to determine the biodistribution of sEVs (<em>n</em> = 2). (b) Ex vivo fluorescence imaging of the sEVs in the individual organs. Fluorescence intensity was quantified using an in vivo imaging system (IVIS).</p></figcaption></figure></section><section id="jex270080-sec-0260"><h3 class="pmc_sec_title">3.6. eEV Induced Potent In Vivo Anti‐Tumour Effects</h3>
<p>Based on the in vitro results, we investigated the in vivo anti‐tumour efficacy of the eEVs using a syngeneic lung cancer mouse model. After subcutaneously injecting LL/2‐Luc2 cells into wild‐type C57BL/6 mice, PBS, cEVs, or eEVs were intravenously administered every 2 days, starting at 5 days post‐injection of the LL/2‐Luc2 cells (Figure <a href="#jex270080-fig-0006" class="usa-link">6a</a>). We sacrificed the mice 17 days after lung cancer inoculation and measured the tumour volume, bioluminescence signals, and weight. In the syngeneic lung cancer mouse model, the eEV‐treated group demonstrated a significant anti‐tumour effect, inhibiting tumour growth by over 42% compared with the control group (Figures <a href="#jex270080-fig-0006" class="usa-link">6a,b</a>). Similarly, treatment with eEVs significantly suppressed the tumour weight compared with the PBS‐ or cEV‐treated groups (Figure <a href="#jex270080-fig-0006" class="usa-link">6c</a>). Specifically, when compared with cEVs, the eEVs inhibited the tumour weight by approximately 30% in the lung cancer mouse model (Figure <a href="#jex270080-fig-0006" class="usa-link">6c</a>). We further observed a reduction of over 43.1% in the spleen weight of eEV‐treated mice compared with that of the cEV‐treated group (Figure <a href="#jex270080-fig-0006" class="usa-link">6d</a>). These results suggest that eEVs prevent splenomegaly and exhibit potent anti‐tumour efficacy. To analyse the effect of eEVs on cancer cells in vivo, the expression of Ki‐67 expression in tumour tissues was evaluated using IHC. Quantitative analysis revealed that Ki‐67 levels were significantly reduced in the eEV‐treated group compared to both PBS‐ and cEV‐treated mice (Figure <a href="#jex270080-fig-0006" class="usa-link">6e</a>).</p>
<figure class="fig xbox font-sm" id="jex270080-fig-0006"><h4 class="obj_head">FIGURE 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f8e/12365385/a0a732f2dab1/JEX2-4-e70080-g006.jpg" loading="lazy" id="jats-graphic-13" height="377" width="800" alt="FIGURE 6"></p>
<div class="p text-right font-secondary"><a href="figure/jex270080-fig-0006/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Anti‐tumour effects of eEVs in lung cancer mouse models. (a) Schematic design (top) and tumour volume of the xenografts (bottom). cEVs or eEVs were administered at 1 × 10<sup>10</sup> particles each, every other day through intravenous injection. (b) Representative images (left) and total flux analysis (right) of the LL/2‐Luc2 cells in each treatment group (PBS control, cEVs, and eEVs) using an IVIS. (c) Weight of the excised tumours from each group. (d) Quantification of the spleen size in each group. (e) Representative immunohistochemistry (IHC) images (top) and quantitative analysis (bottom) of Ki‐67–positive area in tumour sections. Scale bars: 100 µm. The data are presented as the mean ± SEM (<em>n</em> = 5 mice/group). *<em>p</em> &lt; 0.05; **<em>p</em> &lt; 0.01; ***<em>p</em> &lt; 0.001; ****<em>p</em> &lt; 0.0001.</p></figcaption></figure></section><section id="jex270080-sec-0270"><h3 class="pmc_sec_title">3.7. Combination of eEVs With an αPD‐1 Ab Enhances Therapeutic Potential</h3>
<p>We evaluated whether eEVs could enhance the therapeutic efficacy of αPD‐1 Ab in a combination treatment. Five days after the subcutaneous injection of LL/2‐Luc2 lung cancer cells into the wild‐type C57BL/6 mice, we administered PBS or eEVs intravenously every 2 days and IgG Ab or αPD‐1 Ab intraperitoneally every 3 days (Figure <a href="#jex270080-fig-0007" class="usa-link">7a</a>). The αPD‐1 Ab treatment inhibited tumour growth by 66% in the syngeneic lung cancer mouse model compared with the IgG control group. Interestingly, the eEV and αPD‐1 Ab combination treatment had a significant inhibitory effect on tumour growth, showing a reduction of approximately 73% compared with the control group (Figures <a href="#jex270080-fig-0007" class="usa-link">7a,b</a>). The eEVs, along with αPD‐1 Ab, suppressed the tumour weight by approximately 61.5% compared with the control IgG group, whereas αPD‐1 Ab treatment alone decreased tumour weight by only 20.7% (Figure <a href="#jex270080-fig-0007" class="usa-link">7c</a>). In particular, the combination treatment significantly reduced tumour weight by approximately 51.5% compared with the αPD‐1 Ab alone. Additionally, splenomegaly was reduced by more than 32.9% in the combination treatment group compared with the IgG Ab‐treated control group (Figure <a href="#jex270080-fig-0007" class="usa-link">7d</a>). These findings confirmed that the combination treatment of eEVs and αPD‐1 Ab improved the therapeutic potential compared with monotherapy.</p>
<figure class="fig xbox font-sm" id="jex270080-fig-0007"><h4 class="obj_head">FIGURE 7.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f8e/12365385/03d9ed23dc7a/JEX2-4-e70080-g008.jpg" loading="lazy" id="jats-graphic-15" height="457" width="800" alt="FIGURE 7"></p>
<div class="p text-right font-secondary"><a href="figure/jex270080-fig-0007/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Effect of the combination of eEVs and anti‐PD‐1 antibody (αPD‐1 Ab) in syngeneic lung cancer models. (a) The therapeutic design (top) and tumour volume of the xenografts were measured either in eEV monotherapy or in combination therapy with αPD‐1 Ab. (b) Representative images (left) and bar graphs (right) of the LL/2‐Luc2 cells in each group (treatment with IgG control, αPD‐1 Ab and PBS, and αPD‐1 Ab and eEVs) using an IVIS. (c) Weight of the excised tumours from each group. (d) Quantification of the spleen size in each group. The data are presented as the mean ± SEM (<em>n</em> = 5 mice/group). *<em>p</em> &lt; 0.05; **<em>p</em> &lt; 0.01; ***<em>p</em> &lt; 0.001.</p></figcaption></figure></section></section><section id="jex270080-sec-0280"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>In this study, we genetically engineered human NK‐92 cells using lentiviruses to produce NK‐sEVs that expressed IL15 and cetuximab on their surface. These eEVs demonstrated anti‐tumour effects through two mechanisms: the direct killing of lung cancer cells and an indirect effect that increased immune cell‐mediated cytotoxicity. Cetuximab, tethered to the surface of the eEVs, recognized EGFR in NSCLC, which enhanced their cancer‐targeting abilities. Treatment with eEVs exhibited significant anti‐tumour effects, and when used in combination with an immune checkpoint inhibitor (ICI), αPD‐1 Ab, it further enhanced the anti‐tumour efficacy. These findings indicate the potential clinical applicability of NK‐sEVs as an alternative immunotherapeutic agent.</p>
<p>Immunotherapy uses the body's immune system to suppress or eliminate tumour cells by enhancing the anti‐tumour immune response. Represented by ICIs such as the PD‐1/PD‐L1 blockade, immunotherapy stands out for cancer treatment because of its ability to provide sustained efficacy and allow for long‐term survival (Yin et al. <a href="#jex270080-bib-0052" class="usa-link" aria-describedby="jex270080-bib-0052">2021</a>; Mandal et al. <a href="#jex270080-bib-0025" class="usa-link" aria-describedby="jex270080-bib-0025">2019</a>). Ongoing clinical trials are currently evaluating the effectiveness of various anti‐PD‐1/PD‐L1 antibodies as primary, secondary, or adjuvant therapies (Saleh et al. <a href="#jex270080-bib-0034" class="usa-link" aria-describedby="jex270080-bib-0034">2018</a>; Mayor et al. <a href="#jex270080-bib-0027" class="usa-link" aria-describedby="jex270080-bib-0027">2016</a>). Notably, PD‐1/PD‐L1 inhibitors demonstrate promising anti‐tumour activity against NSCLC. However, it has become increasingly evident that immunotherapy is not universally effective for most patients, and only a minority, approximately 20% of patients with NSCLC, benefit from its effects (Seya et al. <a href="#jex270080-bib-0035" class="usa-link" aria-describedby="jex270080-bib-0035">2018</a>). Consequently, there is a recognized need for various combination therapies, leading to numerous endeavours in this direction. In our results, the combination treatment of eEVs and αPD‐1 Ab exhibited enhanced anti‐tumour effects in a lung cancer mouse model compared to the treatment with αPD‐1 Ab alone (Figure <a href="#jex270080-fig-0007" class="usa-link">7</a>). These results suggest that eEVs, with their ability to directly kill NSCLC cells and activate immune cells (Figures <a href="#jex270080-fig-0003" class="usa-link">3a,b</a> and Figure <a href="#jex270080-fig-0004" class="usa-link">4</a>), exhibited a greater synergistic effect, which resulted in cancer growth inhibition. These findings suggest a potential alternative for patients with lung cancer who are resistant to ICI therapy, indicating a new direction for further research and clinical investigation.</p>
<p>Cytokines are small glycoproteins and polypeptides that are secreted for intercellular signalling within an organism, and act in an autocrine or paracrine manner. These bioactive molecules hold considerable importance in modulating the immune system by regulating the immune cells activity (Lin and Leonard <a href="#jex270080-bib-0021" class="usa-link" aria-describedby="jex270080-bib-0021">2019</a>). Notably, they exert a significant influence on the modulation of the TME by facilitating cancer antigen presentation, initiating T cell priming and activation, promoting the infiltration of effector T cells into the TME, and triggering the activation of NK cells (Chen and Mellman <a href="#jex270080-bib-0002" class="usa-link" aria-describedby="jex270080-bib-0002">2013</a>). Recent research has focused on various cytokines that enhance the immunotherapeutic effects of NK cells. IL12, IL15, and IL18 enhance the proliferation and cytotoxicity of NK cells in solid tumours (Leong et al. <a href="#jex270080-bib-0018" class="usa-link" aria-describedby="jex270080-bib-0018">2014</a>; Widowati et al. <a href="#jex270080-bib-0047" class="usa-link" aria-describedby="jex270080-bib-0047">2020</a>; Mirjačić Martinović et al. <a href="#jex270080-bib-0029" class="usa-link" aria-describedby="jex270080-bib-0029">2015</a>; Zhuang et al. <a href="#jex270080-bib-0056" class="usa-link" aria-describedby="jex270080-bib-0056">2019</a>). Moreover, several studies have indicated that cytokine stimulation increases the cytotoxic activity of NK‐sEVs. For instance, IL15 treatment enhanced NK‐sEV cytotoxicity against breast cancer and glioblastoma, and NK‐sEVs stimulated with IL15 and IL21 exhibited potent anti‐tumour effects against liver cancer (Zhu et al. <a href="#jex270080-bib-0055" class="usa-link" aria-describedby="jex270080-bib-0055">2019</a>; Kim et al. <a href="#jex270080-bib-0017" class="usa-link" aria-describedby="jex270080-bib-0017">2023</a>). In our results, the surface expression of IL15 on NK cells further enhanced the anti‐tumour capabilities of eEVs compared with cEVs through an autocrine manner (Figures <a href="#jex270080-fig-0003" class="usa-link">3c,d</a>). Beyond our results, Zhu et al. demonstrated that IL15 stimulation in NK cells was associated with increased sEV production rates (Zhu et al. <a href="#jex270080-bib-0055" class="usa-link" aria-describedby="jex270080-bib-0055">2019</a>). Addressing the challenge of the naturally low yield of secreted sEVs, which is an important obstacle for clinical application, our engineering approach involving IL15 surface expression on NK cells aims to amplify sEV production and enhance anti‐tumour capabilities. This strategy provides the possibility of progressing to clinical applications.</p>
<p>sEVs are considered effective nanocarriers of endogenous or artificially loaded biological contents (Parada et al. <a href="#jex270080-bib-0032" class="usa-link" aria-describedby="jex270080-bib-0032">2021</a>). Characteristics such as rapid internalization into recipient cells, low immunogenicity even upon repeated administration, and the potential to modify cargo molecules or surface membranes for specific targeting have made sEVs powerful therapeutic agents (Parada et al. <a href="#jex270080-bib-0032" class="usa-link" aria-describedby="jex270080-bib-0032">2021</a>). However, sEVs do not inherently possess specificity for the target cells. The intravenous administration of exogenous or therapeutic sEVs in mammals is mainly associated with their accumulation in the liver, spleen, lungs, and gastrointestinal tract, with limited access to the target cells (Wiklander et al. <a href="#jex270080-bib-0048" class="usa-link" aria-describedby="jex270080-bib-0048">2015</a>). To overcome these limitations, previous studies have employed EV surface antibody engineering to facilitate cell‐specific delivery. Cetuximab was designed to bind to the extracellular domain of EGFR and has been used for the treatment of colorectal, cervical, and lung cancer, as well as other malignancies. Based on this, it was confirmed that cetuximab tethering to the surface of NK‐sEVs significantly enhanced their antibody‐mediated cancer cell targeting potential (Figure <a href="#jex270080-fig-0002" class="usa-link">2</a> and Figure <a href="#jex270080-fig-0005" class="usa-link">5</a>). The use of other antibodies targeting proteins that are specifically expressed on cancer cells (e.g., HER2) provides a potential route for future treatment of various cancers and is not limited to NSCLC. This suggests the expandable potential for the application of this anti‐tumour treatment and provides a new perspective for cancer therapy.</p>
<p>sEV‐based therapies have emerged as promising strategies for lung cancer treatment, attracting significant attention due to their capability as natural delivery vehicles for therapeutic molecules. Among the various sEV‐based approaches, NK cell‐derived sEVs, mesenchymal stem cell (MSC)‐derived sEVs, and dendritic cell (DC)‐derived sEVs exhibit inherent anti‐tumour properties, reflecting the unique characteristics of the cells from which they are derived (Enomoto et al. <a href="#jex270080-bib-0008" class="usa-link" aria-describedby="jex270080-bib-0008">2022</a>; Markov et al. <a href="#jex270080-bib-0026" class="usa-link" aria-describedby="jex270080-bib-0026">2019</a>; Shan et al. <a href="#jex270080-bib-0036" class="usa-link" aria-describedby="jex270080-bib-0036">2024</a>; Weng et al. <a href="#jex270080-bib-0046" class="usa-link" aria-describedby="jex270080-bib-0046">2021</a>). To enhance the therapeutic efficacy of sEVs, these vesicles can be loaded with agents such as miRNAs or chemical drugs (e.g., doxorubicin), thereby increasing their potential as treatment modalities (Li et al. <a href="#jex270080-bib-0019" class="usa-link" aria-describedby="jex270080-bib-0019">2022</a>). However, the inherent lack of targeting specificity in sEVs leads to nonspecific distribution to non‐target cells, significantly limiting their effective accumulation at tumour sites. Recently, the strategy of expressing antibodies on the surface of engineered sEVs has been reported as a means to overcome these challenges. This includes the development of platforms that facilitate sEV delivery through the expression of Fc regions on sEVs, allowing for the attachment of antibodies (C. Liu, X. Liu, et al. <a href="#jex270080-bib-0022" class="usa-link" aria-describedby="jex270080-bib-0022">2022</a>). Additionally, studies have progressed to expressing antibodies on sEVs derived from DCs, further enhancing their targeting capabilities (Wang et al. <a href="#jex270080-bib-0045" class="usa-link" aria-describedby="jex270080-bib-0045">2023</a>). Chien et al. demonstrated the in vitro and in vivo EGFR‐mediated tumour‐targeting efficacy of HEK 293 cell‐derived sEVs expressing cetuximab (Chien et al. <a href="#jex270080-bib-0004" class="usa-link" aria-describedby="jex270080-bib-0004">2024</a>). Similarly, engineered CD8<sup>+</sup> T cell‐derived sEVs expressing cetuximab mediated specific interactions with EGFR on A549 lung cancer cells in vitro (Cho et al. <a href="#jex270080-bib-0005" class="usa-link" aria-describedby="jex270080-bib-0005">2023</a>). Building on these findings, we propose an innovative approach that leverages the intrinsic anti‐tumour properties of immune cell‐derived sEVs. In this study, the developed eEVs demonstrated enhanced tumour‐targeting capabilities and anti‐tumour effects compared to control sEVs (cEVs) (Figures <a href="#jex270080-fig-0002" class="usa-link">2</a>, <a href="#jex270080-fig-0003" class="usa-link">3</a>, <a href="#jex270080-fig-0004" class="usa-link">4</a>, <a href="#jex270080-fig-0005" class="usa-link">5</a>, <a href="#jex270080-fig-0006" class="usa-link">6</a>). Furthermore, through genetic engineering, as demonstrated in previous studies, IL15, which induces NK cell activation, was attached to the cell surface, enabling IL15 to function in an autocrine manner (Shin et al. <a href="#jex270080-bib-0037" class="usa-link" aria-describedby="jex270080-bib-0037">2022</a>; Jung et al. <a href="#jex270080-bib-0012" class="usa-link" aria-describedby="jex270080-bib-0012">2022</a>). This allows for a higher payload of anti‐tumour substances within the cargo of NK‐sEVs (Figure <a href="#jex270080-fig-0003" class="usa-link">3d</a>). This engineering approach has resulted in NK‐sEVs with enhanced anti‐tumour efficacy. This sEV engineering approach offers a valuable strategy for enhancing the therapeutic effectiveness of other sEV types, such as MSC‐sEVs and DC‐sEVs, which possess inherent anti‐tumour properties. This approach is anticipated to become a leading sEV‐based therapeutic platform for maximizing their anti‐tumour potential. While this study was specifically designed to evaluate engineered NK‐sEVs as a therapeutic platform, we acknowledge that the inclusion of non‐NK‐derived sEVs engineered with IL15 and cetuximab would provide greater clarity in distinguishing the effects of surface modifications from the intrinsic properties of NK‐sEVs.</p>
<p>Recent research has highlighted the significant anti‐tumour efficacy of NK‐sEVs, underscoring their potential as promising cancer therapeutics (Zhu et al. <a href="#jex270080-bib-0055" class="usa-link" aria-describedby="jex270080-bib-0055">2019</a>; Si et al. <a href="#jex270080-bib-0038" class="usa-link" aria-describedby="jex270080-bib-0038">2024</a>; Hatami et al. <a href="#jex270080-bib-0009" class="usa-link" aria-describedby="jex270080-bib-0009">2023</a>). However, several critical challenges must be addressed to successfully translate these therapies into clinical applications. In particular, understanding the long‐term effects of repeated NK‐sEV administrations is crucial, with a focus on maintaining sustained therapeutic efficacy while assessing potential side effects, such as immune reactions and the development of resistance. Although there are no studies specifically examining the long‐term administration of NK‐sEVs, it is important to consider that prolonged sEV treatments could potentially lead to increased scarring and remodelling in the ischaemic myocardium due to the proliferation of fibroblasts (Jung et al. <a href="#jex270080-bib-0013" class="usa-link" aria-describedby="jex270080-bib-0013">2017</a>). Therefore, determining optimal dosing strategies and administration frequencies is essential to maximize therapeutic outcomes while minimizing potential risks. In addition to safety concerns, the clinical application of NK‐sEVs faces substantial manufacturing and regulatory challenges. Achieving scalable and reproducible production with consistent quality is particularly difficult for immune cell–derived EVs, as donor variability, activation status, and culture conditions can affect both yield and function. Furthermore, ensuring long‐term storage stability and preserving the biological activity of engineered sEVs remains an active area of investigation. Several technical strategies, including the use of bioreactor‐based NK cell expansion and purification methods such as TFF and size exclusion chromatography, are being explored to support production at a clinical scale that meets regulatory standards. To enhance the therapeutic utility of sEVs, previous studies have employed cytokine stimulation, surface antibody engineering, and drug loading within sEVs (Herrmann et al. <a href="#jex270080-bib-0010" class="usa-link" aria-describedby="jex270080-bib-0010">2021</a>; Takahashi and Takakura <a href="#jex270080-bib-0040" class="usa-link" aria-describedby="jex270080-bib-0040">2023</a>; Kim et al. <a href="#jex270080-bib-0016" class="usa-link" aria-describedby="jex270080-bib-0016">2024</a>). In line with these approaches, our study introduces a dual‐functional platform in which NK‐sEVs are engineered to express both IL15 and cetuximab on their surface. This design enhances the intrinsic anti‐tumour activity of the vesicles and promotes immune cell stimulation and tumour‐specific targeting. While this strategy may reduce the need for systemic cytokine administration, the inclusion of IL15 may still lead to unintended immune activation. Although no overt toxicity was observed in our in vivo models, this does not eliminate the need for thorough safety evaluation. Comprehensive preclinical testing, such as cytokine release profiling, biodistribution analysis, immune cell activation studies, and dose‐escalation experiments, will be essential to support the clinical translation of this engineered NK‐sEV platform.</p>
<p>In this proof‐of‐concept study, we engineered NK‐sEVs with IL15 and cetuximab tethered to their surface. Even though the eEVs exhibited significant anti‐tumour effects compared with the cEVs, there is a lack of understanding regarding the anti‐tumour mechanism of eEVs. We observed an increase in the levels of the representative cytotoxic molecules within the manipulated NK cells (Figure <a href="#jex270080-fig-0003" class="usa-link">3c</a>). Additionally, we confirmed an upregulation of granzyme B expression, a representative cytotoxic substance, in the eEVs (Figure <a href="#jex270080-fig-0003" class="usa-link">3d</a>). However, this result alone does not sufficiently explain the enhanced anti‐tumour effects of eEVs. To elucidate the enhanced anti‐tumour mechanism of eEVs, it is necessary to identify the altered molecules, such as miRNA, RNA, and proteins, by profiling the internal contents of sEVs. According to a previous study that employed a similar strategy, the expression of IL2 on the surface of T cell‐derived sEVs (IL2‐sEVs) induced an autocrine‐based stimulation of T cells, which led to a dramatic alteration in the internal contents of the sEVs (C. Liu, X. Liu, et al. <a href="#jex270080-bib-0022" class="usa-link" aria-describedby="jex270080-bib-0022">2022</a>). Increased miR‐181a‐3p in internally reprogrammed IL2‐sEVs inhibited the activity of regulatory T cells and enhanced the activity of CD8<sup>+</sup> T cells. Additionally, miR‐181a‐3p and miR‐223‐3p significantly reduced PD‐L1 protein levels in melanoma cells. This study demonstrated an anti‐tumour mechanism in melanoma through increased miRNA content within the IL2‐sEVs. Given these findings, future studies should investigate the internal content changes in NK‐sEVs that contribute to the enhanced anti‐tumour effects of eEVs.</p>
<p>In conclusion, these findings demonstrate that sEVs derived from NK cells, through surface engineering, target cancer cells, thus proving to be a novel cancer immunotherapy with potent anti‐tumour efficacy. Furthermore, we expect that the use of eEVs, either alone or in combination with traditional immunotherapy, could result in substantial progress in cancer therapy.</p></section><section id="jex270080-sec-0290"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>
<strong>Sung‐Min Kang</strong>: conceptualization (equal), data curation (equal), formal analysis (equal), funding acquisition (equal), investigation (equal), methodology (equal), writing–original draft (equal), writing–review and editing (equal). <strong>Dokyung Jung</strong>: conceptualization (equal); data curation (equal), formal analysis (equal), investigation (equal), methodology (equal), writing–original draft (supporting). <strong>Soojeong Noh</strong>: writing–original draft (supporting), writing–review and editing (supporting). <strong>Sanghee Shin</strong>: writing–original draft (supporting), writing–review and editing (supporting). <strong>Minju Kim</strong>: data curation (supporting), investigation (supporting). <strong>Hanchae Cho</strong>: investigation (supporting), writing–review and editing (equal). <strong>Byungheon Lee</strong>: funding acquisition (equal). <strong>Kyungmoo Yea</strong>: conceptualization (equal), funding acquisition (equal), project administration (equal), resources (equal), supervision (equal), writing–original draft (equal), writing–review and editing (equal). <strong>Moon‐Chang Baek</strong>: conceptualization (equal), funding acquisition (equal), project administration (equal), resources (equal), supervision (equal), writing–original draft (equal), writing–review and editing (equal).</p></section><section id="jex270080-sec-0310"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflicts of interest.</p></section><section id="sec31"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="jex270080-supinfo-0001"></section><section class="sm xbox font-sm" id="jex270080-supitem-0001"><div class="caption p"><p>
<strong>Supplementary Materials</strong>: jex270080‐sup‐0001‐SupMat.docx</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12365385/bin/JEX2-4-e70080-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">JEX2-4-e70080-s001.docx</a><sup> (1,012.7KB, docx) </sup>
</div></div></section></section><section id="jex270080-sec-0300" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Animal use was approved by the Kyungpook National University (KNU) Institutional Animal Care and Use Committees (IACUCs; Approve number: 2021‐0141).</p></section><section id="notes1"><p>


Kang, S.‐M.
, Jung D., Noh S., et al. 2025. “Surface‐Engineered Natural Killer Cell‐Derived Small Extracellular Vesicles Induce Potent Anti‐Tumour Effects in Lung Cancer Cells.” Journal of Extracellular Biology
4, no. 8: 4, e70080. 10.1002/jex2.70080

</p>
<section id="fn-group1" class="fn-group"><div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="jex270080-note-0001"><p>Sung‐Min Kang and Dokyung Jung are the co‐first authors.</p></div>
<div class="fn p" id="jex270080-note-0002"><p>Moon‐Chang Baek and Kyungmoo Yea contributed equally to this work.</p></div>
<div class="fn p" id="jex270080-note-0003"><p>
<strong>Funding</strong>: This work was supported by the National Cancer Center, Korea (NCC‐203205); the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (RS‐2023‐NR077266 and RS‐2021‐NR060094); and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (RS‐2023‐00249737 and RS‐2020‐NR049955).</p></div>
</div></section></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Kyungmoo Yea, Email: ykm31@dgist.ac.kr.</p>
<p>Moon‐Chang Baek, Email: mcbaek@knu.ac.kr.</p></section><section id="jex270080-sec-0330"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></section><section id="jex270080-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="jex270080-bibl-0001_sec2"><ol class="ref-list font-sm">
<li id="jex270080-bib-0001">
<cite>

Cerwenka, A.
, and Lanier L. L.. 2001. “Natural Killer Cells, Viruses and Cancer.” Nature Reviews Immunology
1: 41–49. 10.1038/35095564.</cite> [<a href="https://doi.org/10.1038/35095564" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11905813/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Immunology&amp;title=Natural%20Killer%20Cells,%20Viruses%20and%20Cancer&amp;author=A.%20Cerwenka&amp;author=L.%20L.%20Lanier&amp;volume=1&amp;publication_year=2001&amp;pages=41-49&amp;pmid=11905813&amp;doi=10.1038/35095564&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0002">
<cite>

Chen, D. S.
, and Mellman I.. 2013. “Oncology Meets Immunology: The Cancer‐Immunity Cycle.” Immunity
39: 1–10. 10.1016/j.immuni.2013.07.012.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2013.07.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23890059/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=Oncology%20Meets%20Immunology:%20The%20Cancer%E2%80%90Immunity%20Cycle&amp;author=D.%20S.%20Chen&amp;author=I.%20Mellman&amp;volume=39&amp;publication_year=2013&amp;pages=1-10&amp;pmid=23890059&amp;doi=10.1016/j.immuni.2013.07.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0003">
<cite>

Cheng, Y.
, Zhang T., and Xu Q.. 2021. “Therapeutic Advances in Non‐Small Cell Lung Cancer: Focus on Clinical Development of Targeted Therapy and Immunotherapy.” MedComm
2: 692–729. 10.1002/mco2.105.
</cite> [<a href="https://doi.org/10.1002/mco2.105" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8706764/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34977873/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=MedComm&amp;title=Therapeutic%20Advances%20in%20Non%E2%80%90Small%20Cell%20Lung%20Cancer:%20Focus%20on%20Clinical%20Development%20of%20Targeted%20Therapy%20and%20Immunotherapy&amp;author=Y.%20Cheng&amp;author=T.%20Zhang&amp;author=Q.%20Xu&amp;volume=2&amp;publication_year=2021&amp;pages=692-729&amp;pmid=34977873&amp;doi=10.1002/mco2.105&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0004">
<cite>

Chien, S.‐T.
, Huang Y.‐J., Huang M.‐Y., et al. 2024. “Maximizing Oxaliplatin's Impact on EGFR Plus Colorectal Cancer Through Targeted Extracellular Vesicles.” Cancer Nanotechnology
15: 45. 10.1186/s12645-024-00284-0.</cite> [<a href="https://doi.org/10.1186/s12645-024-00284-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Nanotechnology&amp;title=Maximizing%20Oxaliplatin's%20Impact%20on%20EGFR%20Plus%20Colorectal%20Cancer%20Through%20Targeted%20Extracellular%20Vesicles&amp;author=S.%E2%80%90T.%20Chien&amp;author=Y.%E2%80%90J.%20Huang&amp;author=M.%E2%80%90Y.%20Huang&amp;volume=15&amp;publication_year=2024&amp;pages=45&amp;doi=10.1186/s12645-024-00284-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0005">
<cite>

Cho, H.
, Jung I., Ju H., Baek M. C., and Yea K.. 2023. “Engineered CD8(+) T Cell‐Derived Extracellular Vesicles Induce Enhanced Anti‐Cancer Efficacy and Targeting to Lung Cancer Cells.” Cytokine
169: 156249. 10.1016/j.cyto.2023.156249.
</cite> [<a href="https://doi.org/10.1016/j.cyto.2023.156249" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37290276/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cytokine&amp;title=Engineered%20CD8(+)%20T%20Cell%E2%80%90Derived%20Extracellular%20Vesicles%20Induce%20Enhanced%20Anti%E2%80%90Cancer%20Efficacy%20and%20Targeting%20to%20Lung%20Cancer%20Cells&amp;author=H.%20Cho&amp;author=I.%20Jung&amp;author=H.%20Ju&amp;author=M.%20C.%20Baek&amp;author=K.%20Yea&amp;volume=169&amp;publication_year=2023&amp;pages=156249&amp;pmid=37290276&amp;doi=10.1016/j.cyto.2023.156249&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0006">
<cite>

Choi, D.
, Montermini L., Jeong H., Sharma S., Meehan B., and Rak J.. 2019. “Mapping Subpopulations of Cancer Cell‐Derived Extracellular Vesicles and Particles by Nano‐Flow Cytometry.” ACS Nano
13: 10499–10511. 10.1021/acsnano.9b04480.
</cite> [<a href="https://doi.org/10.1021/acsnano.9b04480" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31469961/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ACS%20Nano&amp;title=Mapping%20Subpopulations%20of%20Cancer%20Cell%E2%80%90Derived%20Extracellular%20Vesicles%20and%20Particles%20by%20Nano%E2%80%90Flow%20Cytometry&amp;author=D.%20Choi&amp;author=L.%20Montermini&amp;author=H.%20Jeong&amp;author=S.%20Sharma&amp;author=B.%20Meehan&amp;volume=13&amp;publication_year=2019&amp;pages=10499-10511&amp;pmid=31469961&amp;doi=10.1021/acsnano.9b04480&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0007">
<cite>

El Andaloussi, S.
, Mäger I., Breakefield X. O., and Wood M. J. A.. 2013. “Extracellular Vesicles: Biology and Emerging Therapeutic Opportunities.” Nature Reviews Drug Discovery
12: 347–357. 10.1038/nrd3978.
</cite> [<a href="https://doi.org/10.1038/nrd3978" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23584393/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Drug%20Discovery&amp;title=Extracellular%20Vesicles:%20Biology%20and%20Emerging%20Therapeutic%20Opportunities&amp;author=S.%20El%20Andaloussi&amp;author=I.%20M%C3%A4ger&amp;author=X.%20O.%20Breakefield&amp;author=M.%20J.%20A.%20Wood&amp;volume=12&amp;publication_year=2013&amp;pages=347-357&amp;pmid=23584393&amp;doi=10.1038/nrd3978&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0008">
<cite>

Enomoto, Y.
, Li P., Jenkins L. M., et al. 2022. “Cytokine‐Enhanced Cytolytic Activity of Exosomes From NK Cells.” Cancer Gene Therapy
29: 734–749. 10.1038/s41417-021-00352-2.
</cite> [<a href="https://doi.org/10.1038/s41417-021-00352-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9209332/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34316033/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Gene%20Therapy&amp;title=Cytokine%E2%80%90Enhanced%20Cytolytic%20Activity%20of%20Exosomes%20From%20NK%20Cells&amp;author=Y.%20Enomoto&amp;author=P.%20Li&amp;author=L.%20M.%20Jenkins&amp;volume=29&amp;publication_year=2022&amp;pages=734-749&amp;pmid=34316033&amp;doi=10.1038/s41417-021-00352-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0009">
<cite>

Hatami, Z.
, Hashemi Z. S., Eftekhary M., et al. 2023. “Natural Killer Cell‐Derived Exosomes for Cancer Immunotherapy: Innovative Therapeutics Art.” Cancer Cell International
23: 157. 10.1186/s12935-023-02996-6.
</cite> [<a href="https://doi.org/10.1186/s12935-023-02996-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10403883/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37543612/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell%20International&amp;title=Natural%20Killer%20Cell%E2%80%90Derived%20Exosomes%20for%20Cancer%20Immunotherapy:%20Innovative%20Therapeutics%20Art&amp;author=Z.%20Hatami&amp;author=Z.%20S.%20Hashemi&amp;author=M.%20Eftekhary&amp;volume=23&amp;publication_year=2023&amp;pages=157&amp;pmid=37543612&amp;doi=10.1186/s12935-023-02996-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0010">
<cite>

Herrmann, I. K.
, Wood M. J. A., and Fuhrmann G.. 2021. “Extracellular Vesicles as a Next‐Generation Drug Delivery Platform.” Nature Nanotechnology
16: 748–759. 10.1038/s41565-021-00931-2.</cite> [<a href="https://doi.org/10.1038/s41565-021-00931-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34211166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Nanotechnology&amp;title=Extracellular%20Vesicles%20as%20a%20Next%E2%80%90Generation%20Drug%20Delivery%20Platform&amp;author=I.%20K.%20Herrmann&amp;author=M.%20J.%20A.%20Wood&amp;author=G.%20Fuhrmann&amp;volume=16&amp;publication_year=2021&amp;pages=748-759&amp;pmid=34211166&amp;doi=10.1038/s41565-021-00931-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0011">
<cite>

Ji, H.
, Li D., Chen L., et al. 2006. “The Impact of Human EGFR Kinase Domain Mutations on Lung Tumorigenesis and In Vivo Sensitivity to EGFR‐targeted Therapies.” Cancer Cell
9: 485–495. 10.1016/j.ccr.2006.04.022.
</cite> [<a href="https://doi.org/10.1016/j.ccr.2006.04.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16730237/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=The%20Impact%20of%20Human%20EGFR%20Kinase%20Domain%20Mutations%20on%20Lung%20Tumorigenesis%20and%20In%20Vivo%20Sensitivity%20to%20EGFR%E2%80%90targeted%20Therapies&amp;author=H.%20Ji&amp;author=D.%20Li&amp;author=L.%20Chen&amp;volume=9&amp;publication_year=2006&amp;pages=485-495&amp;pmid=16730237&amp;doi=10.1016/j.ccr.2006.04.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0012">
<cite>

Jung, D.
, Shin S., Kang S.‐M., et al. 2022. “Reprogramming of T Cell‐Derived Small Extracellular Vesicles Using IL2 Surface Engineering Induces Potent Anti‐Cancer Effects Through miRNA Delivery.” Journal of Extracellular Vesicles
11: e12287. 10.1002/jev2.12287.
</cite> [<a href="https://doi.org/10.1002/jev2.12287" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9709340/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36447429/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Extracellular%20Vesicles&amp;title=Reprogramming%20of%20T%20Cell%E2%80%90Derived%20Small%20Extracellular%20Vesicles%20Using%20IL2%20Surface%20Engineering%20Induces%20Potent%20Anti%E2%80%90Cancer%20Effects%20Through%20miRNA%20Delivery&amp;author=D.%20Jung&amp;author=S.%20Shin&amp;author=S.%E2%80%90M.%20Kang&amp;volume=11&amp;publication_year=2022&amp;pages=e12287&amp;pmid=36447429&amp;doi=10.1002/jev2.12287&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0013">
<cite>

Jung, J. H.
, Fu X. B., and Yang P. C.. 2017. “Exosomes Generated From iPSC‐Derivatives New Direction for Stem Cell Therapy in Human Heart Diseases.” Circulation Research
120: 407–417. 10.1161/Circresaha.116.309307.
</cite> [<a href="https://doi.org/10.1161/Circresaha.116.309307" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5260934/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28104773/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation%20Research&amp;title=Exosomes%20Generated%20From%20iPSC%E2%80%90Derivatives%20New%20Direction%20for%20Stem%20Cell%20Therapy%20in%20Human%20Heart%20Diseases&amp;author=J.%20H.%20Jung&amp;author=X.%20B.%20Fu&amp;author=P.%20C.%20Yang&amp;volume=120&amp;publication_year=2017&amp;pages=407-417&amp;pmid=28104773&amp;doi=10.1161/Circresaha.116.309307&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0014">
<cite>

Kaban, K.
, Hinterleitner C., Zhou Y., et al. 2021. “Therapeutic Silencing of BCL‐2 Using NK Cell‐Derived Exosomes as a Novel Therapeutic Approach in Breast Cancer.” Cancers
13: 2397. 10.3390/cancers13102397.
</cite> [<a href="https://doi.org/10.3390/cancers13102397" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8156181/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34063475/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Therapeutic%20Silencing%20of%20BCL%E2%80%902%20Using%20NK%20Cell%E2%80%90Derived%20Exosomes%20as%20a%20Novel%20Therapeutic%20Approach%20in%20Breast%20Cancer&amp;author=K.%20Kaban&amp;author=C.%20Hinterleitner&amp;author=Y.%20Zhou&amp;volume=13&amp;publication_year=2021&amp;pages=2397&amp;pmid=34063475&amp;doi=10.3390/cancers13102397&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0015">
<cite>

Kang, Y.‐T.
, Niu Z., Hadlock T., et al. 2021. “On‐Chip Biogenesis of Circulating NK Cell‐Derived Exosomes in Non‐Small Cell Lung Cancer Exhibits Antitumoral Activity.” Advancement of Science
8: 2003747. 10.1002/advs.202003747.</cite> [<a href="https://doi.org/10.1002/advs.202003747" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7967048/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33747745/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advancement%20of%20Science&amp;title=On%E2%80%90Chip%20Biogenesis%20of%20Circulating%20NK%20Cell%E2%80%90Derived%20Exosomes%20in%20Non%E2%80%90Small%20Cell%20Lung%20Cancer%20Exhibits%20Antitumoral%20Activity&amp;author=Y.%E2%80%90T.%20Kang&amp;author=Z.%20Niu&amp;author=T.%20Hadlock&amp;volume=8&amp;publication_year=2021&amp;pages=2003747&amp;pmid=33747745&amp;doi=10.1002/advs.202003747&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0016">
<cite>

Kim, H. I.
, Park J., Zhu Y., Wang X., Han Y., and Zhang D.. 2024. “Recent Advances in Extracellular Vesicles for Therapeutic Cargo Delivery.” Experimental &amp; Molecular Medicine
56: 836–849. 10.1038/s12276-024-01201-6.
</cite> [<a href="https://doi.org/10.1038/s12276-024-01201-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11059217/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38556545/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Experimental%20&amp;%20Molecular%20Medicine&amp;title=Recent%20Advances%20in%20Extracellular%20Vesicles%20for%20Therapeutic%20Cargo%20Delivery&amp;author=H.%20I.%20Kim&amp;author=J.%20Park&amp;author=Y.%20Zhu&amp;author=X.%20Wang&amp;author=Y.%20Han&amp;volume=56&amp;publication_year=2024&amp;pages=836-849&amp;pmid=38556545&amp;doi=10.1038/s12276-024-01201-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0017">
<cite>

Kim, I. Y.
, Kim H. Y., Song H. W., Park J. O., Choi Y. H., and Choi E.. 2023. “Functional Enhancement of Exosomes Derived From NK Cells by IL‐15 and IL‐21 Synergy Against Hepatocellular Carcinoma Cells: The Cytotoxicity and Apoptosis In Vitro Study.” Heliyon
9: e16962. 10.1016/j.heliyon.2023.e16962.
</cite> [<a href="https://doi.org/10.1016/j.heliyon.2023.e16962" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10361042/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37484408/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heliyon&amp;title=Functional%20Enhancement%20of%20Exosomes%20Derived%20From%20NK%20Cells%20by%20IL%E2%80%9015%20and%20IL%E2%80%9021%20Synergy%20Against%20Hepatocellular%20Carcinoma%20Cells:%20The%20Cytotoxicity%20and%20Apoptosis%20In%20Vitro%20Study&amp;author=I.%20Y.%20Kim&amp;author=H.%20Y.%20Kim&amp;author=H.%20W.%20Song&amp;author=J.%20O.%20Park&amp;author=Y.%20H.%20Choi&amp;volume=9&amp;publication_year=2023&amp;pages=e16962&amp;pmid=37484408&amp;doi=10.1016/j.heliyon.2023.e16962&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0018">
<cite>

Leong, J. W.
, Chase J. M., Romee R., et al. 2014. “Preactivation With IL‐12, IL‐15, and IL‐18 Induces CD25 and a Functional High‐Affinity IL‐2 Receptor on Human Cytokine‐Induced Memory‐Like Natural Killer Cells.” Biology of Blood and Marrow Transplantation
20: 463–473. 10.1016/j.bbmt.2014.01.006.
</cite> [<a href="https://doi.org/10.1016/j.bbmt.2014.01.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3959288/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24434782/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biology%20of%20Blood%20and%20Marrow%20Transplantation&amp;title=Preactivation%20With%20IL%E2%80%9012,%20IL%E2%80%9015,%20and%20IL%E2%80%9018%20Induces%20CD25%20and%20a%20Functional%20High%E2%80%90Affinity%20IL%E2%80%902%20Receptor%20on%20Human%20Cytokine%E2%80%90Induced%20Memory%E2%80%90Like%20Natural%20Killer%20Cells&amp;author=J.%20W.%20Leong&amp;author=J.%20M.%20Chase&amp;author=R.%20Romee&amp;volume=20&amp;publication_year=2014&amp;pages=463-473&amp;pmid=24434782&amp;doi=10.1016/j.bbmt.2014.01.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0019">
<cite>

Li, H.
, Xu W., Li F., et al. 2022. “Amplification of Anticancer Efficacy by Co‐Delivery of Doxorubicin and Lonidamine With Extracellular Vesicles.” Drug Delivery
29: 192–202. 10.1080/10717544.2021.2023697.
</cite> [<a href="https://doi.org/10.1080/10717544.2021.2023697" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8741238/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34984953/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Delivery&amp;title=Amplification%20of%20Anticancer%20Efficacy%20by%20Co%E2%80%90Delivery%20of%20Doxorubicin%20and%20Lonidamine%20With%20Extracellular%20Vesicles&amp;author=H.%20Li&amp;author=W.%20Xu&amp;author=F.%20Li&amp;volume=29&amp;publication_year=2022&amp;pages=192-202&amp;pmid=34984953&amp;doi=10.1080/10717544.2021.2023697&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0020">
<cite>

Li, X.
, Corbett A. L., Taatizadeh E., et al. 2019. “Challenges and Opportunities in Exosome Research‐Perspectives From Biology, Engineering, and Cancer Therapy.” APL Bioengineering
3: 011503. 10.1063/1.5087122.
</cite> [<a href="https://doi.org/10.1063/1.5087122" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6481742/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31069333/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=APL%20Bioengineering&amp;title=Challenges%20and%20Opportunities%20in%20Exosome%20Research%E2%80%90Perspectives%20From%20Biology,%20Engineering,%20and%20Cancer%20Therapy&amp;author=X.%20Li&amp;author=A.%20L.%20Corbett&amp;author=E.%20Taatizadeh&amp;volume=3&amp;publication_year=2019&amp;pages=011503&amp;pmid=31069333&amp;doi=10.1063/1.5087122&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0021">
<cite>

Lin, J. X.
, and Leonard W. J.. 2019. “Fine‐Tuning Cytokine Signals.” Annual Review of Immunology
37: 295–324. 10.1146/annurev-immunol-042718-041447.</cite> [<a href="https://doi.org/10.1146/annurev-immunol-042718-041447" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10822674/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30649989/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annual%20Review%20of%20Immunology&amp;title=Fine%E2%80%90Tuning%20Cytokine%20Signals&amp;author=J.%20X.%20Lin&amp;author=W.%20J.%20Leonard&amp;volume=37&amp;publication_year=2019&amp;pages=295-324&amp;pmid=30649989&amp;doi=10.1146/annurev-immunol-042718-041447&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0022">
<cite>

Liu, C.
, Liu X., Xiang X., et al. 2022. “A Nanovaccine for Antigen Self‐Presentation and Immunosuppression Reversal as a Personalized Cancer Immunotherapy Strategy.” Nature Nanotechnology
17: 531–540. 10.1038/s41565-022-01098-0.</cite> [<a href="https://doi.org/10.1038/s41565-022-01098-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35410368/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Nanotechnology&amp;title=A%20Nanovaccine%20for%20Antigen%20Self%E2%80%90Presentation%20and%20Immunosuppression%20Reversal%20as%20a%20Personalized%20Cancer%20Immunotherapy%20Strategy&amp;author=C.%20Liu&amp;author=X.%20Liu&amp;author=X.%20Xiang&amp;volume=17&amp;publication_year=2022&amp;pages=531-540&amp;pmid=35410368&amp;doi=10.1038/s41565-022-01098-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0023">
<cite>

Liu, G. H.
, Chen T., Zhang X., Ma X. L., and Shi H. S.. 2022. “Small Molecule Inhibitors Targeting the Cancers.” MedComm
3: e181. 10.1002/mco2.181.
</cite> [<a href="https://doi.org/10.1002/mco2.181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9560750/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36254250/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=MedComm&amp;title=Small%20Molecule%20Inhibitors%20Targeting%20the%20Cancers&amp;author=G.%20H.%20Liu&amp;author=T.%20Chen&amp;author=X.%20Zhang&amp;author=X.%20L.%20Ma&amp;author=H.%20S.%20Shi&amp;volume=3&amp;publication_year=2022&amp;pages=e181&amp;pmid=36254250&amp;doi=10.1002/mco2.181&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0024">
<cite>

Luan, X.
, Sansanaphongpricha K., Myers I., Chen H., Yuan H., and Sun D.. 2017. “Engineering Exosomes as Refined Biological Nanoplatforms for Drug Delivery.” Acta Pharmacologica Sinica
38: 754–763. 10.1038/aps.2017.12.
</cite> [<a href="https://doi.org/10.1038/aps.2017.12" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5520184/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28392567/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Pharmacologica%20Sinica&amp;title=Engineering%20Exosomes%20as%20Refined%20Biological%20Nanoplatforms%20for%20Drug%20Delivery&amp;author=X.%20Luan&amp;author=K.%20Sansanaphongpricha&amp;author=I.%20Myers&amp;author=H.%20Chen&amp;author=H.%20Yuan&amp;volume=38&amp;publication_year=2017&amp;pages=754-763&amp;pmid=28392567&amp;doi=10.1038/aps.2017.12&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0025">
<cite>

Mandal, R.
, Samstein R. M., Lee K.‐W., et al. 2019. “Genetic Diversity of Tumors With Mismatch Repair Deficiency Influences Anti‐PD‐1 Immunotherapy Response.” Science
364: 485–491. 10.1126/science.aau0447.
</cite> [<a href="https://doi.org/10.1126/science.aau0447" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6685207/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31048490/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Genetic%20Diversity%20of%20Tumors%20With%20Mismatch%20Repair%20Deficiency%20Influences%20Anti%E2%80%90PD%E2%80%901%20Immunotherapy%20Response&amp;author=R.%20Mandal&amp;author=R.%20M.%20Samstein&amp;author=K.%E2%80%90W.%20Lee&amp;volume=364&amp;publication_year=2019&amp;pages=485-491&amp;pmid=31048490&amp;doi=10.1126/science.aau0447&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0026">
<cite>

Markov, O.
, Oshchepkova A., and Mironova N.. 2019. “Immunotherapy Based on Dendritic Cell‐Targeted/‐Derived Extracellular Vesicles‐A Novel Strategy for Enhancement of the Anti‐Tumor Immune Response.” Frontiers in Pharmacology
10: 1152. 10.3389/fphar.2019.01152.
</cite> [<a href="https://doi.org/10.3389/fphar.2019.01152" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6798004/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31680949/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Pharmacology&amp;title=Immunotherapy%20Based%20on%20Dendritic%20Cell%E2%80%90Targeted/%E2%80%90Derived%20Extracellular%20Vesicles%E2%80%90A%20Novel%20Strategy%20for%20Enhancement%20of%20the%20Anti%E2%80%90Tumor%20Immune%20Response&amp;author=O.%20Markov&amp;author=A.%20Oshchepkova&amp;author=N.%20Mironova&amp;volume=10&amp;publication_year=2019&amp;pages=1152&amp;pmid=31680949&amp;doi=10.3389/fphar.2019.01152&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0027">
<cite>

Mayor, M.
, Yang N., Sterman D., Jones D. R., and Adusumilli P. S.. 2016. “Immunotherapy for Non‐Small Cell Lung Cancer: Current Concepts and Clinical Trials.” European Journal of Cardio‐Thoracic Surgery
49: 1324–1333. 10.1093/ejcts/ezv371.
</cite> [<a href="https://doi.org/10.1093/ejcts/ezv371" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4851162/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26516195/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Cardio%E2%80%90Thoracic%20Surgery&amp;title=Immunotherapy%20for%20Non%E2%80%90Small%20Cell%20Lung%20Cancer:%20Current%20Concepts%20and%20Clinical%20Trials&amp;author=M.%20Mayor&amp;author=N.%20Yang&amp;author=D.%20Sterman&amp;author=D.%20R.%20Jones&amp;author=P.%20S.%20Adusumilli&amp;volume=49&amp;publication_year=2016&amp;pages=1324-1333&amp;pmid=26516195&amp;doi=10.1093/ejcts/ezv371&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0028">
<cite>

Melaiu, O.
, Lucarini V., Cifaldi L., and Fruci D.. 2020. “Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.” Frontiers in Immunology
10: 3038. 10.3389/fimmu.2019.03038.
</cite> [<a href="https://doi.org/10.3389/fimmu.2019.03038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6985149/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32038612/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Immunology&amp;title=Influence%20of%20the%20Tumor%20Microenvironment%20on%20NK%20Cell%20Function%20in%20Solid%20Tumors&amp;author=O.%20Melaiu&amp;author=V.%20Lucarini&amp;author=L.%20Cifaldi&amp;author=D.%20Fruci&amp;volume=10&amp;publication_year=2020&amp;pages=3038&amp;pmid=32038612&amp;doi=10.3389/fimmu.2019.03038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0029">
<cite>

Mirjačić Martinović, K.
, Babović N., Džodić R., Jurišić V., Matković S., and Konjević G.. 2015. “Favorable In Vitro Effects of Combined IL‐12 and IL‐18 Treatment on NK Cell Cytotoxicity and CD25 Receptor Expression in Metastatic Melanoma Patients.” Journal of Translational Medicine
13: 120. 10.1186/s12967-015-0479-z.
</cite> [<a href="https://doi.org/10.1186/s12967-015-0479-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4421987/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25889680/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Translational%20Medicine&amp;title=Favorable%20In%20Vitro%20Effects%20of%20Combined%20IL%E2%80%9012%20and%20IL%E2%80%9018%20Treatment%20on%20NK%20Cell%20Cytotoxicity%20and%20CD25%20Receptor%20Expression%20in%20Metastatic%20Melanoma%20Patients&amp;author=K.%20Mirja%C4%8Di%C4%87%20Martinovi%C4%87&amp;author=N.%20Babovi%C4%87&amp;author=R.%20D%C5%BEodi%C4%87&amp;author=V.%20Juri%C5%A1i%C4%87&amp;author=S.%20Matkovi%C4%87&amp;volume=13&amp;publication_year=2015&amp;pages=120&amp;pmid=25889680&amp;doi=10.1186/s12967-015-0479-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0030">
<cite>

Mukohara, T.
, Engelman J. A., Hanna N. H., et al. 2005. “Differential Effects of Gefitinib and Cetuximab on Non‐Small‐Cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations.” JNCI: Journal of the National Cancer Institute
97: 1185–1194. 10.1093/jnci/dji238.
</cite> [<a href="https://doi.org/10.1093/jnci/dji238" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16106023/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JNCI:%20Journal%20of%20the%20National%20Cancer%20Institute&amp;title=Differential%20Effects%20of%20Gefitinib%20and%20Cetuximab%20on%20Non%E2%80%90Small%E2%80%90Cell%20Lung%20Cancers%20Bearing%20Epidermal%20Growth%20Factor%20Receptor%20Mutations&amp;author=T.%20Mukohara&amp;author=J.%20A.%20Engelman&amp;author=N.%20H.%20Hanna&amp;volume=97&amp;publication_year=2005&amp;pages=1185-1194&amp;pmid=16106023&amp;doi=10.1093/jnci/dji238&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0031">
<cite>

Neviani, P.
, Wise P. M., Murtadha M., et al. 2019. “Natural Killer‐Derived Exosomal miR‐186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms.” Cancer Research
79: 1151–1164. 10.1158/0008-5472.CAN-18-0779.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-18-0779" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6428417/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30541743/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Research&amp;title=Natural%20Killer%E2%80%90Derived%20Exosomal%20miR%E2%80%90186%20Inhibits%20Neuroblastoma%20Growth%20and%20Immune%20Escape%20Mechanisms&amp;author=P.%20Neviani&amp;author=P.%20M.%20Wise&amp;author=M.%20Murtadha&amp;volume=79&amp;publication_year=2019&amp;pages=1151-1164&amp;pmid=30541743&amp;doi=10.1158/0008-5472.CAN-18-0779&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0032">
<cite>

Parada, N.
, Romero‐Trujillo A., Georges N., and Alcayaga‐Miranda F.. 2021. “Camouflage Strategies for Therapeutic Exosomes Evasion From Phagocytosis.” Journal of Advanced Research
31: 61–74. 10.1016/j.jare.2021.01.001.
</cite> [<a href="https://doi.org/10.1016/j.jare.2021.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8240105/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34194832/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Advanced%20Research&amp;title=Camouflage%20Strategies%20for%20Therapeutic%20Exosomes%20Evasion%20From%20Phagocytosis&amp;author=N.%20Parada&amp;author=A.%20Romero%E2%80%90Trujillo&amp;author=N.%20Georges&amp;author=F.%20Alcayaga%E2%80%90Miranda&amp;volume=31&amp;publication_year=2021&amp;pages=61-74&amp;pmid=34194832&amp;doi=10.1016/j.jare.2021.01.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0033">
<cite>

Russell, J. H.
, and Ley T. J.. 2002. “Lymphocyte‐Mediated Cytotoxicity.” Annual Review of Immunology
20: 323–370. 10.1146/annurev.immunol.20.100201.131730.</cite> [<a href="https://doi.org/10.1146/annurev.immunol.20.100201.131730" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11861606/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annual%20Review%20of%20Immunology&amp;title=Lymphocyte%E2%80%90Mediated%20Cytotoxicity&amp;author=J.%20H.%20Russell&amp;author=T.%20J.%20Ley&amp;volume=20&amp;publication_year=2002&amp;pages=323-370&amp;pmid=11861606&amp;doi=10.1146/annurev.immunol.20.100201.131730&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0034">
<cite>

Saleh, K.
, Eid R., Haddad F. G., Khalife‐Saleh N., and Kourie H. R.. 2018. “New Developments in the Management of Head and Neck Cancer—Impact of Pembrolizumab.” Therapeutics and Clinical Risk Management
14: 295–303. 10.2147/TCRM.S125059.
</cite> [<a href="https://doi.org/10.2147/TCRM.S125059" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5822846/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29497306/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therapeutics%20and%20Clinical%20Risk%20Management&amp;title=New%20Developments%20in%20the%20Management%20of%20Head%20and%20Neck%20Cancer%E2%80%94Impact%20of%20Pembrolizumab&amp;author=K.%20Saleh&amp;author=R.%20Eid&amp;author=F.%20G.%20Haddad&amp;author=N.%20Khalife%E2%80%90Saleh&amp;author=H.%20R.%20Kourie&amp;volume=14&amp;publication_year=2018&amp;pages=295-303&amp;pmid=29497306&amp;doi=10.2147/TCRM.S125059&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0035">
<cite>

Seya, T.
, Takeda Y., Takashima K., Yoshida S., Azuma M., and Matsumoto M.. 2018. “Adjuvant Immunotherapy for Cancer: both Dendritic Cell‐Priming and Check‐Point Inhibitor Blockade Are Required for Immunotherapy.” Proceedings of the Japan Academy, Series B ‐ Physical and Biological Sciences
94: 153–160. 10.2183/pjab.94.011.
</cite> [<a href="https://doi.org/10.2183/pjab.94.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5909060/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29526974/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings%20of%20the%20Japan%20Academy,%20Series%20B%20%E2%80%90%20Physical%20and%20Biological%20Sciences&amp;title=Adjuvant%20Immunotherapy%20for%20Cancer:%20both%20Dendritic%20Cell%E2%80%90Priming%20and%20Check%E2%80%90Point%20Inhibitor%20Blockade%20Are%20Required%20for%20Immunotherapy&amp;author=T.%20Seya&amp;author=Y.%20Takeda&amp;author=K.%20Takashima&amp;author=S.%20Yoshida&amp;author=M.%20Azuma&amp;volume=94&amp;publication_year=2018&amp;pages=153-160&amp;pmid=29526974&amp;doi=10.2183/pjab.94.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0036">
<cite>

Shan, C.
, Liang Y., Wang K., and Li P. F.. 2024. “Mesenchymal Stem Cell‐Derived Extracellular Vesicles in Cancer Therapy Resistance: From Biology to Clinical Opportunity.” International Journal of Biological Sciences
20: 347–366. 10.7150/ijbs.88500.
</cite> [<a href="https://doi.org/10.7150/ijbs.88500" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10750277/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38164177/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Biological%20Sciences&amp;title=Mesenchymal%20Stem%20Cell%E2%80%90Derived%20Extracellular%20Vesicles%20in%20Cancer%20Therapy%20Resistance:%20From%20Biology%20to%20Clinical%20Opportunity&amp;author=C.%20Shan&amp;author=Y.%20Liang&amp;author=K.%20Wang&amp;author=P.%20F.%20Li&amp;volume=20&amp;publication_year=2024&amp;pages=347-366&amp;pmid=38164177&amp;doi=10.7150/ijbs.88500&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0037">
<cite>

Shin, S.
, Jung I., Jung D., et al. 2022. “Novel Antitumor Therapeutic Strategy Using CD4(+) T Cell‐Derived Extracellular Vesicles.” Biomaterials
289: 121765. 10.1016/j.biomaterials.2022.121765.
</cite> [<a href="https://doi.org/10.1016/j.biomaterials.2022.121765" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36067566/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomaterials&amp;title=Novel%20Antitumor%20Therapeutic%20Strategy%20Using%20CD4(+)%20T%20Cell%E2%80%90Derived%20Extracellular%20Vesicles&amp;author=S.%20Shin&amp;author=I.%20Jung&amp;author=D.%20Jung&amp;volume=289&amp;publication_year=2022&amp;pages=121765&amp;pmid=36067566&amp;doi=10.1016/j.biomaterials.2022.121765&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0038">
<cite>

Si, C. H.
, Gao J. E., and Ma X.. 2024. “Natural Killer Cell‐Derived Exosome‐Based Cancer Therapy: From Biological Roles to Clinical Significance and Implications.” Molecular Cancer
23: 134. 10.1186/s12943-024-02045-4.
</cite> [<a href="https://doi.org/10.1186/s12943-024-02045-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11218398/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38951879/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cancer&amp;title=Natural%20Killer%20Cell%E2%80%90Derived%20Exosome%E2%80%90Based%20Cancer%20Therapy:%20From%20Biological%20Roles%20to%20Clinical%20Significance%20and%20Implications&amp;author=C.%20H.%20Si&amp;author=J.%20E.%20Gao&amp;author=X.%20Ma&amp;volume=23&amp;publication_year=2024&amp;pages=134&amp;pmid=38951879&amp;doi=10.1186/s12943-024-02045-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0039">
<cite>

Siegel, R. L.
, Miller K. D., Wagle N. S., and Jemal A.. 2023. “Cancer Statistics, 2023.” CA: A Cancer Journal for Clinicians
73: 17–48. 10.3322/caac.21763.
</cite> [<a href="https://doi.org/10.3322/caac.21763" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36633525/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA:%20A%20Cancer%20Journal%20for%20Clinicians&amp;title=Cancer%20Statistics,%202023&amp;author=R.%20L.%20Siegel&amp;author=K.%20D.%20Miller&amp;author=N.%20S.%20Wagle&amp;author=A.%20Jemal&amp;volume=73&amp;publication_year=2023&amp;pages=17-48&amp;pmid=36633525&amp;doi=10.3322/caac.21763&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0040">
<cite>

Takahashi, Y.
, and Takakura Y.. 2023. “Extracellular Vesicle‐Based Therapeutics: Extracellular Vesicles as Therapeutic Targets and Agents.” Pharmacolpgy &amp; Therapeutics
242: 108352. 10.1016/j.pharmthera.2023.108352.</cite> [<a href="https://doi.org/10.1016/j.pharmthera.2023.108352" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36702209/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacolpgy%20&amp;%20Therapeutics&amp;title=Extracellular%20Vesicle%E2%80%90Based%20Therapeutics:%20Extracellular%20Vesicles%20as%20Therapeutic%20Targets%20and%20Agents&amp;author=Y.%20Takahashi&amp;author=Y.%20Takakura&amp;volume=242&amp;publication_year=2023&amp;pages=108352&amp;pmid=36702209&amp;doi=10.1016/j.pharmthera.2023.108352&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0041">
<cite>

Testa, U.
, Castelli G., and Pelosi E.. 2018. “Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.” Cancers
10: 248.
</cite> [<a href="https://doi.org/10.3390/cancers10080248" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6116004/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30060526/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Lung%20Cancers:%20Molecular%20Characterization,%20Clonal%20Heterogeneity%20and%20Evolution,%20and%20Cancer%20Stem%20Cells&amp;author=U.%20Testa&amp;author=G.%20Castelli&amp;author=E.%20Pelosi&amp;volume=10&amp;publication_year=2018&amp;pages=248&amp;pmid=30060526&amp;doi=10.3390/cancers10080248&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0042">
<cite>

Théry, C.
, Zitvogel L., and Amigorena S.. 2002. “Exosomes: Composition, Biogenesis and Function.” Nature Reviews Immunology
2: 569–579. 10.1038/nri855.</cite> [<a href="https://doi.org/10.1038/nri855" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12154376/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Immunology&amp;title=Exosomes:%20Composition,%20Biogenesis%20and%20Function&amp;author=C.%20Th%C3%A9ry&amp;author=L.%20Zitvogel&amp;author=S.%20Amigorena&amp;volume=2&amp;publication_year=2002&amp;pages=569-579&amp;pmid=12154376&amp;doi=10.1038/nri855&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0043">
<cite>

Van Schaeybroeck, S.
, Kyula J., Kelly D. M., et al. 2006. “Chemotherapy‐Induced Epidermal Growth Factor Receptor Activation Determines Response to Combined gefitinib/Chemotherapy Treatment in Non‐Small Cell Lung Cancer Cells.” Molecular Cancer Therapeutics
5: 1154–1165. 10.1158/1535-7163.MCT-05-0446.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-05-0446" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16731747/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cancer%20Therapeutics&amp;title=Chemotherapy%E2%80%90Induced%20Epidermal%20Growth%20Factor%20Receptor%20Activation%20Determines%20Response%20to%20Combined%20gefitinib/Chemotherapy%20Treatment%20in%20Non%E2%80%90Small%20Cell%20Lung%20Cancer%20Cells&amp;author=S.%20Van%20Schaeybroeck&amp;author=J.%20Kyula&amp;author=D.%20M.%20Kelly&amp;volume=5&amp;publication_year=2006&amp;pages=1154-1165&amp;pmid=16731747&amp;doi=10.1158/1535-7163.MCT-05-0446&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0044">
<cite>

Vivier, E.
, Tomasello E., Baratin M., Walzer T., and Ugolini S.. 2008. “Functions of Natural Killer Cells.” Nature Immunology
9: 503–510. 10.1038/ni1582.
</cite> [<a href="https://doi.org/10.1038/ni1582" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18425107/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Immunology&amp;title=Functions%20of%20Natural%20Killer%20Cells&amp;author=E.%20Vivier&amp;author=E.%20Tomasello&amp;author=M.%20Baratin&amp;author=T.%20Walzer&amp;author=S.%20Ugolini&amp;volume=9&amp;publication_year=2008&amp;pages=503-510&amp;pmid=18425107&amp;doi=10.1038/ni1582&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0045">
<cite>

Wang, L. W.
, Wang D., Ye Z. M., and Xu J. B.. 2023. “Engineering Extracellular Vesicles as Delivery Systems in Therapeutic Applications.” Advancement of Science
10: e2300552. 10.1002/advs.202300552.</cite> [<a href="https://doi.org/10.1002/advs.202300552" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10265081/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37080941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advancement%20of%20Science&amp;title=Engineering%20Extracellular%20Vesicles%20as%20Delivery%20Systems%20in%20Therapeutic%20Applications&amp;author=L.%20W.%20Wang&amp;author=D.%20Wang&amp;author=Z.%20M.%20Ye&amp;author=J.%20B.%20Xu&amp;volume=10&amp;publication_year=2023&amp;pages=e2300552&amp;pmid=37080941&amp;doi=10.1002/advs.202300552&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0046">
<cite>

Weng, Z.
, Zhang B., Wu C., et al. 2021. “Therapeutic Roles of Mesenchymal Stem Cell‐Derived Extracellular Vesicles in Cancer.” Journal of Hematology &amp; Oncology
14: 136. 10.1186/s13045-021-01141-y.
</cite> [<a href="https://doi.org/10.1186/s13045-021-01141-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8414028/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34479611/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Hematology%20&amp;%20Oncology&amp;title=Therapeutic%20Roles%20of%20Mesenchymal%20Stem%20Cell%E2%80%90Derived%20Extracellular%20Vesicles%20in%20Cancer&amp;author=Z.%20Weng&amp;author=B.%20Zhang&amp;author=C.%20Wu&amp;volume=14&amp;publication_year=2021&amp;pages=136&amp;pmid=34479611&amp;doi=10.1186/s13045-021-01141-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0047">
<cite>

Widowati, W.
, K Jasaputra D., B Sumitro S., et al. 2020. “Effect of Interleukins (IL‐2, IL‐15, IL‐18) on Receptors Activation and Cytotoxic Activity of Natural Killer Cells in Breast Cancer Cell.” African Health Sciences
20: 822–832. 10.4314/ahs.v20i2.36.
</cite> [<a href="https://doi.org/10.4314/ahs.v20i2.36" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7609126/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33163049/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=African%20Health%20Sciences&amp;title=Effect%20of%20Interleukins%20(IL%E2%80%902,%20IL%E2%80%9015,%20IL%E2%80%9018)%20on%20Receptors%20Activation%20and%20Cytotoxic%20Activity%20of%20Natural%20Killer%20Cells%20in%20Breast%20Cancer%20Cell&amp;author=W.%20Widowati&amp;author=D.%20K%20Jasaputra&amp;author=S.%20B%20Sumitro&amp;volume=20&amp;publication_year=2020&amp;pages=822-832&amp;pmid=33163049&amp;doi=10.4314/ahs.v20i2.36&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0048">
<cite>

Wiklander, O. P. B.
, Nordin J. Z., O'Loughlin A., et al. 2015. “Extracellular Vesicle In Vivo Biodistribution Is Determined by Cell Source, Route of Administration and Targeting.” Journal of Extracellular Vesicles
4: 26316. 10.3402/jev.v4.26316.
</cite> [<a href="https://doi.org/10.3402/jev.v4.26316" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4405624/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25899407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Extracellular%20Vesicles&amp;title=Extracellular%20Vesicle%20In%20Vivo%20Biodistribution%20Is%20Determined%20by%20Cell%20Source,%20Route%20of%20Administration%20and%20Targeting&amp;author=O.%20P.%20B.%20Wiklander&amp;author=J.%20Z.%20Nordin&amp;author=A.%20O'Loughlin&amp;volume=4&amp;publication_year=2015&amp;pages=26316&amp;pmid=25899407&amp;doi=10.3402/jev.v4.26316&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0049">
<cite>

Xu, M.
, Yang Q., Sun X., and Wang Y.. 2020. “Recent Advancements in the Loading and Modification of Therapeutic Exosomes.” Frontiers in Bioengineering and Biotechnology
8: 586130. 10.3389/fbioe.2020.586130.
</cite> [<a href="https://doi.org/10.3389/fbioe.2020.586130" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7686035/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33262977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Bioengineering%20and%20Biotechnology&amp;title=Recent%20Advancements%20in%20the%20Loading%20and%20Modification%20of%20Therapeutic%20Exosomes&amp;author=M.%20Xu&amp;author=Q.%20Yang&amp;author=X.%20Sun&amp;author=Y.%20Wang&amp;volume=8&amp;publication_year=2020&amp;pages=586130&amp;pmid=33262977&amp;doi=10.3389/fbioe.2020.586130&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0050">
<cite>

Xu, R.
, Rai A., Chen M., Suwakulsiri W., Greening D. W., and Simpson R. J.. 2018. “Extracellular Vesicles in Cancer—Implications for Future Improvements in Cancer Care.” Nature Reviews Clinical Oncology
15: 617–638. 10.1038/s41571-018-0036-9.</cite> [<a href="https://doi.org/10.1038/s41571-018-0036-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29795272/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Clinical%20Oncology&amp;title=Extracellular%20Vesicles%20in%20Cancer%E2%80%94Implications%20for%20Future%20Improvements%20in%20Cancer%20Care&amp;author=R.%20Xu&amp;author=A.%20Rai&amp;author=M.%20Chen&amp;author=W.%20Suwakulsiri&amp;author=D.%20W.%20Greening&amp;volume=15&amp;publication_year=2018&amp;pages=617-638&amp;pmid=29795272&amp;doi=10.1038/s41571-018-0036-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0051">
<cite>

Yang, J.‐L.

2004. “Regulation of Epidermal Growth Factor Receptor in human Colon Cancer Cell Lines by Interferon Alpha.” Gut
53: 123–129. 10.1136/gut.53.1.123.
</cite> [<a href="https://doi.org/10.1136/gut.53.1.123" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1773946/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14684586/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=Regulation%20of%20Epidermal%20Growth%20Factor%20Receptor%20in%20human%20Colon%20Cancer%20Cell%20Lines%20by%20Interferon%20Alpha&amp;author=J.%E2%80%90L.%20Yang&amp;volume=53&amp;publication_year=2004&amp;pages=123-129&amp;pmid=14684586&amp;doi=10.1136/gut.53.1.123&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0052">
<cite>

Yin, Z.
, Yu M., Ma T., et al. 2021. “Mechanisms Underlying Low‐Clinical Responses to PD‐1/PD‐L1 Blocking Antibodies in Immunotherapy of Cancer: A Key Role of Exosomal PD‐L1.” Journal for ImmunoTherapy of Cancer
9: e001698. 10.1136/jitc-2020-001698.
</cite> [<a href="https://doi.org/10.1136/jitc-2020-001698" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7818841/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33472857/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20for%20ImmunoTherapy%20of%20Cancer&amp;title=Mechanisms%20Underlying%20Low%E2%80%90Clinical%20Responses%20to%20PD%E2%80%901/PD%E2%80%90L1%20Blocking%20Antibodies%20in%20Immunotherapy%20of%20Cancer:%20A%20Key%20Role%20of%20Exosomal%20PD%E2%80%90L1&amp;author=Z.%20Yin&amp;author=M.%20Yu&amp;author=T.%20Ma&amp;volume=9&amp;publication_year=2021&amp;pages=e001698&amp;pmid=33472857&amp;doi=10.1136/jitc-2020-001698&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0053">
<cite>

Zha, Z.
, Bucher F., Nejatfard A., et al. 2017. “Interferon‐γ Is a Master Checkpoint Regulator of Cytokine‐Induced Differentiation.” Proceedings of the National Academy of Sciences of the United States of America
114: E6867–E6874. 10.1073/pnas.1706915114.
</cite> [<a href="https://doi.org/10.1073/pnas.1706915114" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5565454/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28760993/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20of%20the%20United%20States%20of%20America&amp;title=Interferon%E2%80%90%CE%B3%20Is%20a%20Master%20Checkpoint%20Regulator%20of%20Cytokine%E2%80%90Induced%20Differentiation&amp;author=Z.%20Zha&amp;author=F.%20Bucher&amp;author=A.%20Nejatfard&amp;volume=114&amp;publication_year=2017&amp;pages=E6867-E6874&amp;pmid=28760993&amp;doi=10.1073/pnas.1706915114&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0054">
<cite>

Zhu, L.
, Kalimuthu S., Gangadaran P., et al. 2017. “Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma.” Theranostics
7: 2732–2745. 10.7150/thno.18752.
</cite> [<a href="https://doi.org/10.7150/thno.18752" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5558565/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28819459/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Theranostics&amp;title=Exosomes%20Derived%20From%20Natural%20Killer%20Cells%20Exert%20Therapeutic%20Effect%20in%20Melanoma&amp;author=L.%20Zhu&amp;author=S.%20Kalimuthu&amp;author=P.%20Gangadaran&amp;volume=7&amp;publication_year=2017&amp;pages=2732-2745&amp;pmid=28819459&amp;doi=10.7150/thno.18752&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0055">
<cite>

Zhu, L.
, Kalimuthu S., Oh J. M., et al. 2019. “Enhancement of Antitumor Potency of Extracellular Vesicles Derived From Natural Killer Cells by IL‐15 Priming.” Biomaterials
190–191: 38–50. 10.1016/j.biomaterials.2018.10.034.</cite> [<a href="https://doi.org/10.1016/j.biomaterials.2018.10.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30391801/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomaterials&amp;title=Enhancement%20of%20Antitumor%20Potency%20of%20Extracellular%20Vesicles%20Derived%20From%20Natural%20Killer%20Cells%20by%20IL%E2%80%9015%20Priming&amp;author=L.%20Zhu&amp;author=S.%20Kalimuthu&amp;author=J.%20M.%20Oh&amp;volume=190%E2%80%93191&amp;publication_year=2019&amp;pages=38-50&amp;pmid=30391801&amp;doi=10.1016/j.biomaterials.2018.10.034&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jex270080-bib-0056">
<cite>

Zhuang, L.
, Fulton R. J., Rettman P., et al. 2019. “Activity of IL‐12/15/18 Primed Natural Killer Cells Against Hepatocellular Carcinoma.” Hepatology International
13: 75–83. 10.1007/s12072-018-9909-3.
</cite> [<a href="https://doi.org/10.1007/s12072-018-9909-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6513806/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30467624/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology%20International&amp;title=Activity%20of%20IL%E2%80%9012/15/18%20Primed%20Natural%20Killer%20Cells%20Against%20Hepatocellular%20Carcinoma&amp;author=L.%20Zhuang&amp;author=R.%20J.%20Fulton&amp;author=P.%20Rettman&amp;volume=13&amp;publication_year=2019&amp;pages=75-83&amp;pmid=30467624&amp;doi=10.1007/s12072-018-9909-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ol></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="caption p"><p>
<strong>Supplementary Materials</strong>: jex270080‐sup‐0001‐SupMat.docx</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12365385/bin/JEX2-4-e70080-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">JEX2-4-e70080-s001.docx</a><sup> (1,012.7KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Extracellular Biology are provided here courtesy of <strong>Wiley on behalf of the International Society for Extracellular Vesicles (ISEV)</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/jex2.70080"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/JEX2-4-e70080.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.6 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12365385/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12365385/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365385%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365385/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12365385/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12365385/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40843441/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12365385/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40843441/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12365385/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12365385/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="inPZubp46UBfkTnuyldp93ibWgizBEIajSNoyAzIqPkOb0CNKMHzikbzUukugc8s">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
